Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Lung Cancer Retrieve available abstracts of 541 articles: HTML format

Single Articles

September 2025
1. TAKEMURA C, Yoshida T, Yoshida Y, Inaba Higashiyama R, et al
   Unveiling the molecular and clinical risk landscape of second primary lung cancer in resected non-small cell lung cancer.
   Lung Cancer. 2025;208:108750.
   PubMed     Abstract available
   
   
   
2. WANG J, Cao H, He N, Liu X, et al
   Evolving Trends in Surgically Managed Lung Cancer: A 16-Year Hospital-Based Epidemiological Analysis.
   Lung Cancer. 2025;208:108754.
   PubMed     Abstract available
   
   
   
3. IWAMA E, Sakai K, Harada T, Kanda S, et al
   Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.
   Lung Cancer. 2025;208:108756.
   PubMed     Abstract available
   
   
   
4. ZHANG R, Yan H, Tian F, Jiang Y, et al
   Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs.
   Lung Cancer. 2025;208:108755.
   PubMed     Abstract available
   
   
   
5. SUN F, Banwait MK, Singhal S, Herrmann A, et al
   Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer.
   Lung Cancer. 2025;208:108747.
   PubMed     Abstract available
   
   
   
6. RAJARAM R, Huang Q, Johnson BH, Laxmanan B, et al
   Implications of primary tumor size on overall survival in patients with multifocal T3 non-small cell lung cancer.
   Lung Cancer. 2025;208:108746.
   PubMed     Abstract available
   
   
   
7. UTSUMI H, Yagishita S, Kawajiri K, Torasawa M, et al
   Identification of poor prognostic factors using circulating extracellular vesicles in durvalumab consolidation therapy for locally advanced non-small cell lung cancer.
   Lung Cancer. 2025;208:108732.
   PubMed     Abstract available
   
   
   
8. HUIJS JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, et al
   Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.
   Lung Cancer. 2025;208:108745.
   PubMed     Abstract available
   
   
   
9. CIAMMELLA P, Iori F, Borghetti P, Galaverni M, et al
   Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).
   Lung Cancer. 2025;207:108718.
   PubMed     Abstract available
   
   
   
10. JIANG Y, Lin Y, Mo L, Deng H, et al
    Real-time non-invasive localization in sub-lobar resection for small pulmonary nodules: a noninferiority randomized clinical trial.
    Lung Cancer. 2025;207:108724.
    PubMed     Abstract available
    
    
    
11. ONO S, Taniguchi H, Kuroda K, Hashimoto T, et al
    Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab.
    Lung Cancer. 2025;207:108709.
    PubMed     Abstract available
    
    
    
12. TRUDU L, Rovesti G, Neri G, Pugliese G, et al
    CAR-T for Lung Cancers: Challenges and Innovations.
    Lung Cancer. 2025;207:108711.
    PubMed     Abstract available
    
    
    
13. ZHANG Y, Dai X, Liang J, Yang C, et al
    Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns.
    Lung Cancer. 2025;207:108715.
    PubMed     Abstract available
    
    
    
14. ALAY A, Marin R, Aliagas E, Gausachs M, et al
    Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma.
    Lung Cancer. 2025;207:108679.
    PubMed     Abstract available
    
    
    
15. SHAH R, Buchmeier EL, Kopp HG, Christoph DC, et al
    First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
    Lung Cancer. 2025;207:108702.
    PubMed     Abstract available
    
    
    
16. WANG R, Wei H, Qu C, Bai Y, et al
    Unlocking the potential: tissue mutation abundance as a predictor for third-generation EGFR-TKI efficacy in NSCLC.
    Lung Cancer. 2025;207:108699.
    PubMed     Abstract available
    
    
    
17. KALCHIEM-DEKEL O, Rakocevic R, Toumbacaris N, Tan KS, et al
    Robotic-assisted bronchoscopy for histopathologic subtyping of primary lung adenocarcinoma.
    Lung Cancer. 2025;207:108681.
    PubMed     Abstract available
    
    
    
18. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
    Biomarker landscape in advanced NSCLC: insights from a national prospective registry.
    Lung Cancer. 2025;207:108680.
    PubMed     Abstract available
    
    
    August 2025
19. SHAO T, Yang J, Chen J, Zhang Y, et al
    Retraction notice to "Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis". [Lung Cancer 204 (2025) 108559].
    Lung Cancer. 2025 Aug 31:108719. doi: 10.1016/j.lungcan.2025.108719.
    PubMed    
    
    
    
20. VILLALOBOS M, Ludwig JO, Konig M, Unsold L, et al
    Communication about personal values of patients with advanced lung cancer in the hospital: results of a mixed-methods study.
    Lung Cancer. 2025;208:108729.
    PubMed     Abstract available
    
    
    
21. SHIJUBOU N, Sumi T, Ishigooka T, Naraoka T, et al
    Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer.
    Lung Cancer. 2025;207:108730.
    PubMed    
    
    
    
22. TAFUR A, Sebai A, Shi Z, Wei J, et al
    Polygenic risk score to define risk of cancer-associated thrombosis among patients with lung cancer in a population-based study.
    Lung Cancer. 2025;207:108712.
    PubMed     Abstract available
    
    
    
23. TATEISHI A, Horinouchi H, Kouno N, Takeda K, et al
    Prediction recurrence in stage I epidermal growth factor receptor-mutated non-small cell lung cancer using multi-modal data.
    Lung Cancer. 2025;207:108727.
    PubMed     Abstract available
    
    
    
24. PARK Y, Kang DH, Chung C
    Integrating tumor macroenvironment, microenvironment and mechanobiology with organoid and organ-on-a-chip models for lung cancer immunotherapy.
    Lung Cancer. 2025;207:108726.
    PubMed     Abstract available
    
    
    
25. SMEENK MM, van der Noort V, de Gooijer CJ, Theelen WSME, et al
    Comment on "The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell lung cancer".
    Lung Cancer. 2025;207:108725.
    PubMed    
    
    
    
26. KUROSAKI T, Kanemura H, Otani T, Kawanaka Y, et al
    Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
    Lung Cancer. 2025;207:108723.
    PubMed     Abstract available
    
    
    
27. GUIJOSA A, Rios-Garcia E, Davila-Dupont D, Cruz-Rico G, et al
    Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy.
    Lung Cancer. 2025;207:108722.
    PubMed     Abstract available
    
    
    
28. TU HY, Chen C, Chen C, Cheng C, et al
    Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer.
    Lung Cancer. 2025;208:108716.
    PubMed     Abstract available
    
    
    
29. GRAABAK G, Halvorsen TO, Gronberg BH, Killingberg KT, et al
    Changes in use of radiotherapy for lung cancer - A Norwegian population-based study from 2000 until 2020.
    Lung Cancer. 2025;207:108720.
    PubMed     Abstract available
    
    
    
30. CHEN L, Zhang XH, Mao ZJ, Wang D, et al
    Clinical outcomes and neuroendocrine features of transformed versus primary small-cell lung cancer.
    Lung Cancer. 2025;207:108714.
    PubMed     Abstract available
    
    
    
31. YU Y, Pan Y, Zhou J, Mu S, et al
    Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.
    Lung Cancer. 2025;207:108710.
    PubMed     Abstract available
    
    
    
32. ALI AS, Irfan M
    Second-hand smoke and survival in former smokers with lung cancer: time to act.
    Lung Cancer. 2025 Aug 11:108713. doi: 10.1016/j.lungcan.2025.108713.
    PubMed    
    
    
    
33. NEYT M, Luyten J, Desimpel F, Camberlin C, et al
    An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium.
    Lung Cancer. 2025;207:108697.
    PubMed     Abstract available
    
    
    
34. CUMMINGS AL, Sussell J, Rosettie KL, Moustaid FE, et al
    A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer.
    Lung Cancer. 2025;207:108701.
    PubMed     Abstract available
    
    
    
35. HUBERT J, Moldovanu D, van den Bosch I, de Nijs K, et al
    Impact of recruitment method on informed decision-making in lung cancer screening in the 4-IN-THE-LUNG-RUN trial.
    Lung Cancer. 2025;207:108686.
    PubMed     Abstract available
    
    
    
36. ZHANG Y, Zhao J, Ma Z, Yi J, et al
    Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis.
    Lung Cancer. 2025;207:108700.
    PubMed     Abstract available
    
    
    
37. LIU G, Liu Y, Jing H, Chen T, et al
    Global, regional, and national economic consequences of tracheal, bronchial, and lung cancer.
    Lung Cancer. 2025;207:108685.
    PubMed     Abstract available
    
    
    
38. CHATURVEDI A, Som A
    Transcriptome analysis reveals crucial oncogenic and tumor suppressor miRNAs in lung adenocarcinoma.
    Lung Cancer. 2025;206:108540.
    PubMed     Abstract available
    
    
    
39. LEE J, Kim M, Han HJ, Kim S, et al
    Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study.
    Lung Cancer. 2025;206:108682.
    PubMed     Abstract available
    
    
    
40. PRONSATI N, Liu G, Bauer TM, Felip E, et al
    Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.
    Lung Cancer. 2025;206:108662.
    PubMed     Abstract available
    
    
    
41. FUJINO K, Suda K, Yoshikawa M, Shien K, et al
    Adjuvant therapy in pStage IA1-IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study).
    Lung Cancer. 2025;206:108672.
    PubMed     Abstract available
    
    
    
42. LU F, Lv C, Yang X, Zhuo M, et al
    Icotinib plus chemotherapy as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutant lung adenocarcinoma: a phase II study (NEOIPOWER).
    Lung Cancer. 2025;206:108676.
    PubMed     Abstract available
    
    
    
43. NIEDERMAIER B, Rolf E, Allgauer M, Klotz LV, et al
    Prognostic impact of lepidic growth in intermediate and high-grade lung adenocarcinoma.
    Lung Cancer. 2025;206:108674.
    PubMed     Abstract available
    
    
    
44. LYNCH GA, Symonds J, Morley A, Azubuike-Dyer E, et al
    Serum mesothelin as a response biomarker in pleural mesothelioma.
    Lung Cancer. 2025;206:108670.
    PubMed     Abstract available
    
    
    
45. PANDEY A, Gomez E, Soto A, Jr MA, et al
    A novel murine carcinogen-induced model recapitulates the progression and heterogeneity of human lung adenocarcinoma.
    Lung Cancer. 2025;206:108581.
    PubMed     Abstract available
    
    
    
46. LANGER S, Medenwald D, Vordermark D, Schuette W, et al
    Therapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic review.
    Lung Cancer. 2025;206:108640.
    PubMed     Abstract available
    
    
    
47. ZOLOV S, Chuikov S, Katkam SK, Chockley PJ, et al
    Cell adhesion molecule-1 is a promising target for chimeric antigen receptors in lung adenocarcinoma.
    Lung Cancer. 2025;206:108643.
    PubMed     Abstract available
    
    
    
48. MEDUSA PM, Carro N, Morgillo F, Guida GD, et al
    Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL.
    Lung Cancer. 2025;206:108617.
    PubMed     Abstract available
    
    
    
49. GAGNE A, Alessi JVM, Ricciuti B, Lamberti G, et al
    Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas.
    Lung Cancer. 2025;206:108644.
    PubMed     Abstract available
    
    
    
50. DUMANE V, Runnels J, Flores R, Wolf A, et al
    Long term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma.
    Lung Cancer. 2025;206:108639.
    PubMed     Abstract available
    
    
    July 2025
51. GRONBERG M, Aanerud M, Halvorsen TO, Killingberg KT, et al
    Associations between progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE) and survival in patients with limited-stage small cell lung cancer (LS SCLC) receiving chemoradiotherapy (CRT).
    Lung Cancer. 2025;207:108678.
    PubMed     Abstract available
    
    
    
52. ZENG L, Tong F, Xu X, Song L, et al
    Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.
    Lung Cancer. 2025;207:108684.
    PubMed     Abstract available
    
    
    
53. DINGEMANS AC, Syrigos K, Livi L, Paulus A, et al
    Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
    Lung Cancer. 2025;207:108683.
    PubMed     Abstract available
    
    
    
54. REGUART N, Sampietro-Colom L, Juan-Vidal O, Aguilo M, et al
    Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study).
    Lung Cancer. 2025;206:108677.
    PubMed     Abstract available
    
    
    
55. XENOPHONTOS E, Giaj Levra N, Durieux V, van Geffen WH, et al
    Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group.
    Lung Cancer. 2025;207:108671.
    PubMed     Abstract available
    
    
    
56. AHN Y, Kim SA, Lee SM, Ahn B, et al
    Prognostic impact of extracapsular extension of lymph nodes in resected lung cancer: analysis by new N subcategories and histologic types.
    Lung Cancer. 2025;206:108673.
    PubMed     Abstract available
    
    
    
57. ZHONG D, Sidorenkov G, Poelhekken K, Du Y, et al
    Cost-effectiveness and budget impact of lung cancer screening in time of immunotherapy.
    Lung Cancer. 2025;206:108669.
    PubMed     Abstract available
    
    
    
58. PAULUS A, Zemaitis M, Cicenas S, Zvirbule Z, et al
    Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet.
    Lung Cancer. 2025;206:108664.
    PubMed     Abstract available
    
    
    
59. BOWEN JONES S, Price G, Faivre-Finn C
    An introduction to pragmatic trials in lung cancer research: A multi-faceted approach.
    Lung Cancer. 2025;206:108663.
    PubMed     Abstract available
    
    
    
60. NAIDU SB, Bhamani A, Murray C, Beyer K, et al
    Corrigendum to "AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium". [Lung Cancer 205 (2025) 108610].
    Lung Cancer. 2025 Jul 8:108659. doi: 10.1016/j.lungcan.2025.108659.
    PubMed    
    
    
    
61. FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al
    Corrigendum to "Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study" [Lung Cancer 202 (2025) 108485].
    Lung Cancer. 2025 Jul 8:108658. doi: 10.1016/j.lungcan.2025.108658.
    PubMed    
    
    
    
62. NYKAZA I, An A, Villena-Vargas J, Mount L, et al
    Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States.
    Lung Cancer. 2025;206:108661.
    PubMed     Abstract available
    
    
    
63. CHENG Y, Huang GJ, Chen XB, Zhu HY, et al
    Value of (18)F-FDG PET metabolic parameters combined with the dynamic monitoring of molecular residual disease (MRD) in predicting the prognosis of non-small-cell lung cancer after surgery.
    Lung Cancer. 2025;206:108660.
    PubMed     Abstract available
    
    
    
64. COOLEY ME, Kim SS, Xiong N, Heiling H, et al
    Clearing the air: Empowering high-risk adults with digital tools for smoking cessation and lung cancer screening adoption.
    Lung Cancer. 2025;206:108647.
    PubMed     Abstract available
    
    
    
65. ISO H, Ariyasu R, Fujishima S, Ito M, et al
    Prognostic impact of HNF4alpha expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor.
    Lung Cancer. 2025;205:108631.
    PubMed     Abstract available
    
    
    
66. NAKAI T, Tanaka S, Nagamine H, Miyamoto A, et al
    Application of endobronchial ultrasound-guided cryobiopsy for centrally located intrapulmonary lesions: A retrospective cohort study.
    Lung Cancer. 2025;205:108636.
    PubMed     Abstract available
    
    
    
67. YAN B, Zhang B, Chu T, Zhang W, et al
    Osimertinib combined with anlotinib as first-line treatment in advanced or metastatic NSCLC patients with EGFR mutation: a prospective, single arm, exploratory study.
    Lung Cancer. 2025;205:108627.
    PubMed     Abstract available
    
    
    
68. XIE Y, Yang L, Fang H, Yu C, et al
    Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors.
    Lung Cancer. 2025;205:108593.
    PubMed     Abstract available
    
    
    
69. ZHANG X, Nie Z, van Tuinen M, van de Wauwer C, et al
    Effectiveness and safety of different wire types for preoperative localization of pulmonary nodules: A systematic review and meta-analysis.
    Lung Cancer. 2025;205:108620.
    PubMed     Abstract available
    
    
    
70. NAVANI N, Sharman A, Evison M, Shepherd P, et al
    Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC.
    Lung Cancer. 2025;205:108618.
    PubMed     Abstract available
    
    
    
71. LI JJ, Zhen X, Liu L, Yan X, et al
    Targeting IDH2 promotes antitumor immunity through epigenetic activation of cGAS-STING pathway.
    Lung Cancer. 2025;205:108611.
    PubMed     Abstract available
    
    
    
72. KIM JY, Lee GD, Choi S, Kim HR, et al
    Revisiting margin adequacy in sublobar resection for pure ground-glass opacity adenocarcinomas.
    Lung Cancer. 2025;205:108595.
    PubMed     Abstract available
    
    
    
73. SUZUKI M, Shinozaki-Ushiku A, Yuhara S, Nagano M, et al
    The prognostic impact of extra-alveolar invasion in lung adenocarcinoma.
    Lung Cancer. 2025;205:108612.
    PubMed     Abstract available
    
    
    
74. CHENG S, Zhang R, Yang F, Li J, et al
    Induction therapy with dabrafenib, trametinib, and PD-1 inhibitor and surgical conversion in unresectable stage III non-small cell lung cancers with BRAF V600E mutation: 2 cases.
    Lung Cancer. 2025;205:108592.
    PubMed     Abstract available
    
    
    
75. ABOLFATHI H, Kordahi M, Armero VS, Gagne A, et al
    Clinicopathologic characteristics, co-mutation landscape, and survival outcomes of KRAS-G12D mutant lung adenocarcinoma in comparison to KRAS-G12C and EGFR-mutated subtypes.
    Lung Cancer. 2025;205:108596.
    PubMed     Abstract available
    
    
    June 2025
76. TACHIHARA M, Shoda H, Akazawa Y, Ota T, et al
    Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L).
    Lung Cancer. 2025;206:108637.
    PubMed     Abstract available
    
    
    
77. WANG H, Wang L, Gao N, Li H, et al
    Advances in the treatment of brain metastases in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2025;206:108641.
    PubMed     Abstract available
    
    
    
78. FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
    Transforming lung cancer diagnosis: the role of robotic-assisted bronchoscopy in early detection and staging.
    Lung Cancer. 2025;206:108646.
    PubMed     Abstract available
    
    
    
79. PETERS BJ, van Geffen E, Hilarius D, Bohringer S, et al
    The effectiveness of pembrolizumab maintenance with or without pemetrexed after induction treatment for advanced non-squamous Non-Small-Cell Lung cancer.
    Lung Cancer. 2025;206:108642.
    PubMed     Abstract available
    
    
    
80. SHI Y, Chen R, Xiong Y, Geng R, et al
    MRD status combined with TNM staging optimizes postoperative prognostic stratification in non-small cell lung cancer: a meta-analysis and systematic review.
    Lung Cancer. 2025;206:108634.
    PubMed     Abstract available
    
    
    
81. QIAO K, Zhou T, Dong Y, Liu N, et al
    Relationship between clinicopathological characteristics and PET/CT uptake in lung cancer: [(18)F]FAPI versus [(18)F]FDG.
    Lung Cancer. 2025;206:108645.
    PubMed     Abstract available
    
    
    
82. OLLILA H, Tidjani A, Park BJ, Jones DR, et al
    Nonagenarians: Outcomes after lung cancer surgery.
    Lung Cancer. 2025;206:108632.
    PubMed     Abstract available
    
    
    
83. ZENKE Y, Niho S, Toi Y, Yamaguchi M, et al
    Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study.
    Lung Cancer. 2025;206:108633.
    PubMed     Abstract available
    
    
    
84. MOGHANAKI D, Cameron EA, Garon EB
    Unbridled Enthusiasm for Neoadjuvant Chemoimmunotherapy followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer.
    Lung Cancer. 2025 Jun 20:108628. doi: 10.1016/j.lungcan.2025.108628.
    PubMed    
    
    
    
85. ZHANG M, Tang Y, Liang J, Zhu L, et al
    Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase ? study.
    Lung Cancer. 2025;205:108630.
    PubMed     Abstract available
    
    
    
86. GAWLI CS, Patil BR, Nagpure NR, Patil CR, et al
    Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis.
    Lung Cancer. 2025;205:108629.
    PubMed     Abstract available
    
    
    
87. SUNG H, Jiang C, Schafer EJ, Bandi P, et al
    Burden and trends in subsequent primary lung cancer incidence by sex in the United States.
    Lung Cancer. 2025;205:108625.
    PubMed     Abstract available
    
    
    
88. GEORGE JE, George PS, Krishna JKM, Mathew A, et al
    Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis.
    Lung Cancer. 2025;205:108626.
    PubMed     Abstract available
    
    
    
89. CROUCH SAW, Peindl M, Bencurova E, Caliskan A, et al
    Transcriptome and protein network analyses of 3D-tissue lung cancer models reveal combinatorial targets for KRAS(G12C)-mutation.
    Lung Cancer. 2025;206:108624.
    PubMed     Abstract available
    
    
    
90. PEREZ-PEREZ M, de Sola-Llamas CG, Macias-Garcia L
    Diagnostic accuracy of the Idylla mutation test for detecting EGFR mutations in non-small cell lung cancer: a meta-analysis.
    Lung Cancer. 2025;205:108623.
    PubMed     Abstract available
    
    
    
91. GEMELLI M, Cortinovis D, Carola G, Moretti L, et al
    Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data.
    Lung Cancer. 2025;205:108621.
    PubMed     Abstract available
    
    
    
92. SRIDHAR A, Adjei A, Montori VM, Leventakos K, et al
    Shared decision making for personalized lung cancer care.
    Lung Cancer. 2025 Jun 9:108614. doi: 10.1016/j.lungcan.2025.108614.
    PubMed    
    
    
    
93. WU Y, Xie Y, Chen Y, Li J, et al
    Bronchial washing fluid supernatant serves as a novel liquid biopsy specimen for genome profiling in advanced non-small cell lung cancer.
    Lung Cancer. 2025;205:108622.
    PubMed     Abstract available
    
    
    
94. GUDINA AT, Fitzgibbon ML, Peterson CE, Byrne C, et al
    Geographic disparities in lung cancer screening uptake in the United States using the 2021 United States Preventive Services Task Force Guidelines.
    Lung Cancer. 2025;205:108615.
    PubMed     Abstract available
    
    
    
95. ZHANG Q, Yang Y, Xie M, Zhou Z, et al
    Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.
    Lung Cancer. 2025;205:108616.
    PubMed     Abstract available
    
    
    
96. NAIDU SB, Bhamani A, Murray C, Beyer K, et al
    AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium.
    Lung Cancer. 2025;205:108610.
    PubMed     Abstract available
    
    
    
97. KRAYIM B, Shalata W, Bar J, Moskovitz M, et al
    Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes.
    Lung Cancer. 2025;205:108598.
    PubMed     Abstract available
    
    
    
98. THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
    Corrigendum to "A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers" [Lung Cancer 199 (2025) 108060].
    Lung Cancer. 2025;204:108488.
    PubMed    
    
    
    
99. MA Z, Zhang Y
    A Reply to comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
    Lung Cancer. 2025;204:108537.
    PubMed    
    
    
    
100. ONDER AH
     Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
     Lung Cancer. 2025;204:108536.
     PubMed    
     
     
     
101. ZHANG B, Zhang J
     Comment on "Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study".
     Lung Cancer. 2025;204:108515.
     PubMed    
     
     
     
102. AHMAD WKM, Bedau T, Wang Y, Michels S, et al
     Development and clinical validation of a prognostic algorithm for stroma-tumor ratio quantification in non-small cell lung cancer.
     Lung Cancer. 2025;205:108613.
     PubMed     Abstract available
     
     
     
103. DI LECCE C, Eccher S, Simbolo M, Cocomazzi A, et al
     ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR.
     Lung Cancer. 2025;205:108594.
     PubMed     Abstract available
     
     
     
104. OKADA A, Sakata Y, Oya Y, Sakata S, et al
     Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.
     Lung Cancer. 2025;204:108589.
     PubMed     Abstract available
     
     
     
105. TANAKA S, Nozaki K, Watanabe S, Yanagimura N, et al
     Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study.
     Lung Cancer. 2025;204:108590.
     PubMed     Abstract available
     
     
     
106. RUAN Z, Zeng L, Zhang J, Qin H, et al
     Intrathecal nivolumab and IL-2 for treatment of leptomeningeal metastases in EGFR-mutated lung adenocarcinoma.
     Lung Cancer. 2025;204:108586.
     PubMed     Abstract available
     
     
     
107. CHEN T, Liu F
     Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.
     Lung Cancer. 2025;204:108588.
     PubMed     Abstract available
     
     
     
108. ROMA L, Chijioke O, Flury DV, Kocher GJ, et al
     Unusual relapse dynamics in EGFR-mutated lung adenocarcinoma uncovered by genomic profiling: Insights from a case report.
     Lung Cancer. 2025;204:108587.
     PubMed     Abstract available
     
     
     
109. WHEATLEY-PRICE P, Navani V, Pabani A, Routy B, et al
     Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT --> durvalumab in Canada: The RELEVANCE study.
     Lung Cancer. 2025;204:108583.
     PubMed     Abstract available
     
     
     
110. FACCHINETTI F, Camerini A, Bennati C, Bordi P, et al
     A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).
     Lung Cancer. 2025;204:108580.
     PubMed     Abstract available
     
     
     
111. EKLUND EA, Orgard M, Wallin D, Sayin SI, et al
     Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival.
     Lung Cancer. 2025;204:108573.
     PubMed     Abstract available
     
     
     
112. YAMADA J, Hazama D, Fukui T, Yatani A, et al
     Midazolam with fentanyl for endobronchial ultrasound-guided transbronchial needle aspiration: a randomized, double-blind, phase III study.
     Lung Cancer. 2025;204:108556.
     PubMed     Abstract available
     
     
     
113. SHAO T, Yang J, Chen J, Zhang Y, et al
     Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis.
     Lung Cancer. 2025;204:108559.
     PubMed     Abstract available
     
     
     
114. SUGAI M, Amino Y, Fujishima S, Nibuya K, et al
     Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens.
     Lung Cancer. 2025;204:108555.
     PubMed     Abstract available
     
     
     
115. MURAT-ONANA ML, Ramalingam SS, Janne PA, Gray JE, et al
     EGFR mutation testing across the osimertinib clinical program.
     Lung Cancer. 2025;204:108549.
     PubMed     Abstract available
     
     
     
116. KIM D, Lee J, Jung M, Yim K, et al
     Whole slide image-level classification of malignant effusion cytology using clustering-constrained attention multiple instance learning.
     Lung Cancer. 2025;204:108552.
     PubMed     Abstract available
     
     
     
117. GUCKENBERGER M, Opitz I, Dellaporta T, Curioni-Fontecedro A, et al
     Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.
     Lung Cancer. 2025;204:108553.
     PubMed     Abstract available
     
     
     
118. SERNA-BLASCO R, Mediavilla-Medel P, Medina K, Sala MA, et al
     Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.
     Lung Cancer. 2025;204:108550.
     PubMed     Abstract available
     
     
     May 2025
119. FUJISAKI T, Miyauchi E, Kida G, Miura Y, et al
     Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
     Lung Cancer. 2025;205:108597.
     PubMed     Abstract available
     
     
     
120. MATSUBARA T, Shimokawa M, Wakasu S, Haro A, et al
     Controlling nutritional status predicts postoperative survival and acute exacerbation in resected non-small cell lung cancer with interstitial lung disease.
     Lung Cancer. 2025;205:108591.
     PubMed     Abstract available
     
     
     
121. NOMURA S, Sekino Y, Shiraishi Y, Toi Y, et al
     A treatment-related death predictive score for treatment-naive advanced non-small cell lung cancer.
     Lung Cancer. 2025;204:108584.
     PubMed     Abstract available
     
     
     
122. MOORE WH, Silk M, Bhattacharji P, Pua BB, et al
     Early experience with PEF in the setting of recalcitrant stage IV lung cancer.
     Lung Cancer. 2025;204:108575.
     PubMed     Abstract available
     
     
     
123. LEIGHL NB, Trigo J, Park K, Lee SH, et al
     Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer.
     Lung Cancer. 2025;205:108579.
     PubMed     Abstract available
     
     
     
124. KAKIUCHI Y, Saruwatari K, Tokito T, Iriki T, et al
     Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.
     Lung Cancer. 2025;204:108578.
     PubMed     Abstract available
     
     
     
125. GOURLAY E, Banfill K, Merchant Z, Goodley P, et al
     Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy.
     Lung Cancer. 2025;204:108572.
     PubMed     Abstract available
     
     
     
126. NGUYEN MH, Le MHN, Bui AT, Le NQK, et al
     Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis.
     Lung Cancer. 2025;204:108577.
     PubMed     Abstract available
     
     
     
127. YANG G, Yoon HI, Lim SM, Hong MH, et al
     Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy.
     Lung Cancer. 2025;204:108574.
     PubMed     Abstract available
     
     
     
128. CRESPI V, Delcuratolo MD, Minuti G, Montrone M, et al
     Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer.
     Lung Cancer. 2025;204:108576.
     PubMed     Abstract available
     
     
     
129. WU K, Bi K, Shen M, Tang C, et al
     Decision-making tree model for distinguishing between benign and malignant subpleural pulmonary lesions based on ultrasonic strain elastography.
     Lung Cancer. 2025;203:108547.
     PubMed     Abstract available
     
     
     
130. QIN Y, Mo Y, Li P, Liang X, et al
     Concurrent immunotherapy improves progression-free survival but increases toxicity in unresectable stage III NSCLC.
     Lung Cancer. 2025;203:108544.
     PubMed     Abstract available
     
     
     
131. NADAL E, Martin-Martorell P, Benitez JC, Sala MA, et al
     Efficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.
     Lung Cancer. 2025;203:108545.
     PubMed     Abstract available
     
     
     
132. JIN W, Ding Z, Zhang M, Shen L, et al
     The global burden of mesothelioma and its association with asbestos bans, 1990-2021: a population-based study.
     Lung Cancer. 2025;203:108534.
     PubMed     Abstract available
     
     
     
133. BOSSE Y, Boudreau DK, Saavedra Armero V, Li Z, et al
     Frequency of targetable genetic alterations in resectable lung adenocarcinoma: Results from the LORD project.
     Lung Cancer. 2025;203:108530.
     PubMed     Abstract available
     
     
     
134. LIN YD, Li HJ, Hong HZ, Qi YF, et al
     Genomic profiling of aggressive pathologic features in lung adenocarcinoma.
     Lung Cancer. 2025;203:108460.
     PubMed     Abstract available
     
     
     April 2025
135. LINTAS C, Petti R, Colella G, Cassano I, et al
     Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis.
     Lung Cancer. 2025;204:108560.
     PubMed     Abstract available
     
     
     
136. SHIRAI Y, Shukuya T, Asao T, Takahashi K, et al
     Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study.
     Lung Cancer. 2025;204:108557.
     PubMed     Abstract available
     
     
     
137. CHOUAID C, Bosquet L, Knott C, Li Z, et al
     Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study.
     Lung Cancer. 2025;203:108548.
     PubMed     Abstract available
     
     
     
138. BARSOUK A, Elghawy O, Watts A, Reed-Guy L, et al
     Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
     Lung Cancer. 2025;203:108551.
     PubMed     Abstract available
     
     
     
139. SHIRAISHI Y, Shimose T, Tobino K, Toi Y, et al
     Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002).
     Lung Cancer. 2025;203:108543.
     PubMed     Abstract available
     
     
     
140. LEE JH, Cha S, Ko EJ, Kim W, et al
     Clinical effect of pulmonary rehabilitation during radiotherapy in lung cancer: A randomized controlled trial.
     Lung Cancer. 2025;204:108546.
     PubMed     Abstract available
     
     
     
141. VAES RDW, Cortiula F, Lyu S, Hiltermann TJN, et al
     Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.
     Lung Cancer. 2025;203:108541.
     PubMed     Abstract available
     
     
     
142. DHAEYER S, Missault E, Surmont V, Vermaelen K, et al
     Outcome of temozolomide in relapsed small cell lung cancer: A retrospective single center analysis.
     Lung Cancer. 2025;203:108539.
     PubMed     Abstract available
     
     
     
143. PAN Y, Gu Q
     Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
     Lung Cancer. 2025;203:108532.
     PubMed     Abstract available
     
     
     
144. SARKAR S, Choa E, Manzo LL, Richman I, et al
     Predictors and Uptake of Lung Cancer Screening in the US: An Integrative Literature Review.
     Lung Cancer. 2025;203:108529.
     PubMed     Abstract available
     
     
     
145. WU Q, Li Q, Qin Y
     A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.
     Lung Cancer. 2025;203:108533.
     PubMed     Abstract available
     
     
     
146. AVANCINI A, Giaj-Levra N, Minuti G, Pasqualini G, et al
     Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study.
     Lung Cancer. 2025;203:108531.
     PubMed     Abstract available
     
     
     
147. ROSENLUND L, Guldbrandsen K, Ahlborn LB, Bloch M, et al
     ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.
     Lung Cancer. 2025;203:108528.
     PubMed     Abstract available
     
     
     
148. AN Z, Ning Y, Mei J, Yang C, et al
     Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma.
     Lung Cancer. 2025;202:108507.
     PubMed     Abstract available
     
     
     
149. TAKAMOCHI K, Suzuki K, Okada M, Niho S, et al
     CRES(3)T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.
     Lung Cancer. 2025;202:108506.
     PubMed     Abstract available
     
     
     
150. FAN M, Yan W, Zhuo M, Yu R, et al
     Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report.
     Lung Cancer. 2025;202:108501.
     PubMed     Abstract available
     
     
     
151. MESSEKHER M, Fuchs F, Badr M, Pujol JL, et al
     Gefitinib for EGFR mutated lung adenocarcinoma during pregnancy: A case report with 5-Year Follow-Up.
     Lung Cancer. 2025;202:108456.
     PubMed     Abstract available
     
     
     
152. AHUJA G, Iyer A, Harwood R, Balata H, et al
     Pathological & radiological variables in the diagnosis of bronchopulmonary carcinoids (BPCs) with a focus on Antigen Kiel 67 (Ki-67) proliferation index.
     Lung Cancer. 2025;202:108493.
     PubMed     Abstract available
     
     
     
153. TORASAWA M, Yoshida T, Shiraishi K, Yagishita S, et al
     Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma.
     Lung Cancer. 2025;202:108494.
     PubMed     Abstract available
     
     
     
154. LAVEN IEWG, Franssen AJPM, Gronenschild MHM, Heineman DJ, et al
     National clinical practice patterns of uniportal video-assisted thoracoscopic anatomical lung resections: nationwide population-based data from a clinical audit registry.
     Lung Cancer. 2025;202:108481.
     PubMed     Abstract available
     
     
     
155. GARASSINO MC, He Y, Ahn MJ, Orlov SV, et al
     Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study.
     Lung Cancer. 2025;202:108417.
     PubMed     Abstract available
     
     
     
156. KAWAKITA N, Takehara E, Takeuchi T, Fujimoto K, et al
     Advantages of a larger working channel diameter of ultrathin bronchoscope in cone-beam computed tomography-guided transbronchial biopsy for diagnosing peripheral lung lesions.
     Lung Cancer. 2025;202:108483.
     PubMed     Abstract available
     
     
     
157. SOO RA, Vervita K, Fruh M, Cho BC, et al
     A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.
     Lung Cancer. 2025;202:108454.
     PubMed     Abstract available
     
     
     March 2025
158. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
     Stereotactic body radiation therapy (SBRT) of centrally located medically inoperable early-stage non-small cell lung cancer (T1-T3N0M0) - A subgroup analysis of the expanded HILUS study.
     Lung Cancer. 2025;203:108527.
     PubMed     Abstract available
     
     
     
159. LIU SV, Dziadziuszko R, Viteri S, Cappuzzo F, et al
     ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.
     Lung Cancer. 2025;203:108516.
     PubMed    
     
     
     
160. ADDO S, Lycan T, Soto-Pantoja DR, Tsai YT, et al
     Randomized phase 2 trial of pembrolizumab alone or in combination with low dose chemotherapy for patients with non-small cell lung cancer and poor performance status.
     Lung Cancer. 2025;203:108513.
     PubMed     Abstract available
     
     
     
161. NARGUND RS, Ishizawa S, Eghbalizarch M, Yeh P, et al
     Natural history models for lung Cancer: A scoping review.
     Lung Cancer. 2025;203:108495.
     PubMed     Abstract available
     
     
     
162. ISAKA M, Notsu A, Kojima H, Konno H, et al
     Comparative validation of nodal classifications in resected non-small cell lung cancer based on the anatomical location and number of involved stations.
     Lung Cancer. 2025;203:108511.
     PubMed     Abstract available
     
     
     
163. KESKIN O
     Beyond the Staging: Critical Insights into the Ninth TNM Edition for Lung Cancer.
     Lung Cancer. 2025;203:108502.
     PubMed    
     
     
     
164. TRIWIYANTO T, Alit Pawana I, Luthfiyah S
     Commentary on: Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
     Lung Cancer. 2025;202:108512.
     PubMed    
     
     
     
165. CHEN H, Cai W, Han Y, Zhao Y, et al
     Associations between carbohydrate quality and the survival of, and life expectancy with lung cancer patient: A prospective cohort study.
     Lung Cancer. 2025;203:108508.
     PubMed     Abstract available
     
     
     
166. BOUSEMA JE, Spaans LN, Dijkgraaf MGW, van der Heijden EHFM, et al
     Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up).
     Lung Cancer. 2025;202:108462.
     PubMed     Abstract available
     
     
     
167. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
     Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention.
     Lung Cancer. 2025;202:108500.
     PubMed     Abstract available
     
     
     
168. GOTO Y, Watanabe S, Yanagimura N, Arita M, et al
     The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology.
     Lung Cancer. 2025;202:108505.
     PubMed     Abstract available
     
     
     
169. GOBBINI E, Diallo MH, Pasquier D, Schneider S, et al
     Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.
     Lung Cancer. 2025;202:108499.
     PubMed     Abstract available
     
     
     
170. JABER G, Raffoul C, Diab T, Sinno S, et al
     ALK-EML4 Fusion in Small Cell Lung Cancer: Clinical and Molecular Insights From a Rare Case.
     Lung Cancer. 2025;202:108497.
     PubMed     Abstract available
     
     
     
171. CHO BC, Hayashi H, Lee JS, Lee SH, et al
     Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
     Lung Cancer. 2025;204:108496.
     PubMed     Abstract available
     
     
     
172. VAN DER WEL JWT, de Langen AJ
     Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting.
     Lung Cancer. 2025 Mar 14:108490. doi: 10.1016/j.lungcan.2025.108490.
     PubMed     Abstract available
     
     
     
173. NAVEED F, Khan S, Khan A, Arshad F, et al
     Letter: Alectinib combined with cobimetinib in ALK-rearranged lung cancer: A phase IB study.
     Lung Cancer. 2025;202:108489.
     PubMed    
     
     
     
174. NOUSIAS O, Mandell JD, Anderson KS, Townsend JP, et al
     Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC.
     Lung Cancer. 2025;202:108487.
     PubMed     Abstract available
     
     
     
175. SETO T, Nakane S, Ji L, Ueda Y, et al
     Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent non-small cell lung cancer: Post-marketing surveillance.
     Lung Cancer. 2025;203:108478.
     PubMed     Abstract available
     
     
     
176. VERKOULEN KCHA, Laven IEWG, Daemen JHT, Franssen AJPM, et al
     From data to prediction: Digital chest drain insights into postoperative recovery after lung cancer surgery.
     Lung Cancer. 2025;202:108486.
     PubMed     Abstract available
     
     
     
177. CHO BC, Johnson M, Bar J, Schaefer E, et al
     A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
     Lung Cancer. 2025;202:108492.
     PubMed     Abstract available
     
     
     
178. COOKE S, Nelson D, Argin AA, Laparidou D, et al
     Identifying and exploring patient engagement interventions for people diagnosed with lung cancer: A rapid systematic review.
     Lung Cancer. 2025;202:108484.
     PubMed     Abstract available
     
     
     
179. VINAS F, Goussault H, Boyer L, Bussac GR, et al
     Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study).
     Lung Cancer. 2025;202:108480.
     PubMed     Abstract available
     
     
     
180. FROST MG, Jensen KJ, Jimenez-Solem E, Qvortrup C, et al
     Sex disparities in advanced non-small cell lung cancer survival: A Danish nationwide study.
     Lung Cancer. 2025;202:108485.
     PubMed     Abstract available
     
     
     
181. GRIDELLI C, Attili I, Bennati C, Bironzo P, et al
     Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results?
     Lung Cancer. 2025;202:108482.
     PubMed     Abstract available
     
     
     
182. IGLESIAS MARTINEZ B, Insa A, Cervera Ygual G, Gascon F, et al
     Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis.
     Lung Cancer. 2025;202:108464.
     PubMed     Abstract available
     
     
     
183. UEHARA Y, Izumi H, Kobayashi IS, Matsumoto S, et al
     Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).
     Lung Cancer. 2025;202:108479.
     PubMed     Abstract available
     
     
     
184. GROS L, Yip R, Flores RM, Zhang J, et al
     Prospective cohort study of Suture-Line recurrence and clinical outcomes in stage 1A Non-Small cell lung cancer.
     Lung Cancer. 2025;202:108465.
     PubMed     Abstract available
     
     
     
185. ZHANG M, Deng C, Fu F, Li Y, et al
     Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data.
     Lung Cancer. 2025;201:108451.
     PubMed     Abstract available
     
     
     
186. MORIMOTO K, Yamada T, Furuya N, Tanaka H, et al
     Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
     Lung Cancer. 2025;201:108447.
     PubMed     Abstract available
     
     
     
187. CHOI W, Lee W, Kim Y, Lee SJ, et al
     Immune landscape and novel therapeutic targets of epidermal growth factor receptor and anaplastic lymphoma kinase wild type never-smoker lung adenocarcinoma.
     Lung Cancer. 2025;201:108448.
     PubMed     Abstract available
     
     
     
188. SUBRAMANIAN J, Gregg J, Berktas M, Li J, et al
     EGFR testing practices, treatment choice and clinical outcomes in advanced NSCLC in a real-world setting: A retrospective analysis of a US-based electronic health records database.
     Lung Cancer. 2025;201:108412.
     PubMed     Abstract available
     
     
     
189. CAMIDGE DR, Sugawara S, Kondo M, Kim HR, et al
     Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
     Lung Cancer. 2025;201:108424.
     PubMed     Abstract available
     
     
     
190. YAO Z, Qiu T, Li C, Kong W, et al
     Primary pulmonary adenoid cystic carcinoma: A study of clinicopathological features and molecular alterations in twenty-one cases.
     Lung Cancer. 2025;201:108414.
     PubMed     Abstract available
     
     
     
191. YANG R, Wang H, Liu D, Li W, et al
     Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis.
     Lung Cancer. 2025;205:108458.
     PubMed     Abstract available
     
     
     February 2025
192. SAW SPL, Takano A, Zhou S, Hlaing NO, et al
     EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer.
     Lung Cancer. 2025;202:108463.
     PubMed     Abstract available
     
     
     
193. YANG YH, Kim HE, Park BJ, Lee JG, et al
     Patterns and preoperative risk factors of occult lymph node metastasis in clinical stage I lung cancer.
     Lung Cancer. 2025;202:108461.
     PubMed     Abstract available
     
     
     
194. MA Z, Fu F, Zhang Y, Chen H, et al
     Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: A phase II, prospective cohort study.
     Lung Cancer. 2025;201:108457.
     PubMed     Abstract available
     
     
     
195. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
     Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
     Lung Cancer. 2025 Feb 22:108441. doi: 10.1016/j.lungcan.2025.108441.
     PubMed    
     
     
     
196. JOHNSON M, Younan D, Kent ST, Frias MM, et al
     Corrigendum to "Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC)" [Lung Cancer 197 (2024) 107960].
     Lung Cancer. 2025 Feb 20:108440. doi: 10.1016/j.lungcan.2025.108440.
     PubMed    
     
     
     
197. LEE K, Kim TH, Yong Lee S, Lee YG, et al
     Delayed central nervous system progression with atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer (LU23-15).
     Lung Cancer. 2025;201:108455.
     PubMed     Abstract available
     
     
     
198. GIRARD N, Han JY, Soo RA, Wang K, et al
     Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis.
     Lung Cancer. 2025;201:108450.
     PubMed     Abstract available
     
     
     
199. SATOH H, Okuma Y, Shinno Y, Masuda K, et al
     Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies.
     Lung Cancer. 2025;202:108453.
     PubMed     Abstract available
     
     
     
200. FENG J, Hueniken K, Fan ZJ, Zhan LJ, et al
     Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations.
     Lung Cancer. 2025;204:108452.
     PubMed     Abstract available
     
     
     
201. SANKAR K, Mercer J, Jaeger EB, Godden J, et al
     DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer.
     Lung Cancer. 2025;201:108444.
     PubMed     Abstract available
     
     
     
202. SHAHNAM A, Davis A, Brown LJ, Sullivan I, et al
     Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.
     Lung Cancer. 2025;201:108421.
     PubMed     Abstract available
     
     
     
203. AHN B, Kim D, Ji W, Chun SM, et al
     Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma implicate the needs for tailored treatment strategies.
     Lung Cancer. 2025;201:108445.
     PubMed     Abstract available
     
     
     
204. HUANG L, Petersen RH
     Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung Cancer: Thoracoscopic segmentectomy vs lobectomy.
     Lung Cancer. 2025;201:108438.
     PubMed     Abstract available
     
     
     
205. BOSCH-BARRERA J, Estevez-Garcia P, Martin-Martorell P, Sabatier R, et al
     ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.
     Lung Cancer. 2025;201:108105.
     PubMed     Abstract available
     
     
     
206. AKAMATSU H, Nishikawa T, Takeda Y, Misumi T, et al
     Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.
     Lung Cancer. 2025;201:108437.
     PubMed     Abstract available
     
     
     
207. HE Q, Jiang L, Xu Y, Wang M, et al
     Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis.
     Lung Cancer. 2025;201:108425.
     PubMed     Abstract available
     
     
     
208. ATASEVER F, Sokucu SN, Satici C
     Letter to the editor concerning "Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis".
     Lung Cancer. 2025;201:108423.
     PubMed    
     
     
     
209. FICARRA S, Kang DW, Wilson RL, Gonzalo-Encabo P, et al
     Exercise medicine for individuals diagnosed with Lung Cancer: A systematic review and meta-analysis of health outcomes.
     Lung Cancer. 2025;201:108413.
     PubMed     Abstract available
     
     
     
210. UPRETY D, Abrahami D, Marcum ZA, Li B, et al
     Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.
     Lung Cancer. 2025;201:108436.
     PubMed     Abstract available
     
     
     
211. TAMBO Y, Sone T, Nishi K, Shibata K, et al
     Five-year efficacy and safety of pembrolizumab as first-line treatment in patients with non-small cell lung cancer with PD-L1 tumor proportion score >/=50 %: A multicenter observational study.
     Lung Cancer. 2025;201:108422.
     PubMed     Abstract available
     
     
     
212. SUMI T, Ishigooka T, Matsuura K, Ikeda T, et al
     Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report.
     Lung Cancer. 2025;201:108420.
     PubMed     Abstract available
     
     
     
213. WANG Y, Fujita RA, Fujisawa N, Laskin J, et al
     Mitigation of decline with virtual exercise with lung cancer (MoVE with lung cancer) - A promising approach to enhance physiological strength, improve body composition, and build upon current evidence.
     Lung Cancer. 2025;201:108418.
     PubMed     Abstract available
     
     
     
214. IKEDA S, Ogura T, Miyaoka E, Sekine I, et al
     Survival benefit and potential markers of chemotherapy for elderly and poor performance status patients with advanced non-small cell lung cancer: Results from the Japanese Joint Committee of lung cancer registry database.
     Lung Cancer. 2025;200:108102.
     PubMed     Abstract available
     
     
     
215. REUSS JE, Zaemes J, Gandhi N, Walker P, et al
     Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.
     Lung Cancer. 2025;200:108101.
     PubMed     Abstract available
     
     
     
216. HATA T, Yamada T, Goto Y, Amano A, et al
     Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
     Lung Cancer. 2025;200:108104.
     PubMed     Abstract available
     
     
     
217. NARITA D, Hishinuma E, Ebina-Shibuya R, Miyauchi E, et al
     Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile.
     Lung Cancer. 2025;200:108082.
     PubMed     Abstract available
     
     
     
218. GOMEZ-RANDULFE I, Scanlon LA, Carter M, Moliner L, et al
     First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis.
     Lung Cancer. 2025;200:108084.
     PubMed     Abstract available
     
     
     January 2025
219. DOBKIN J, Stanifer BP, Salvatore M, Eckhardt CM, et al
     Evaluating lung cancer risk factors in adults with interstitial lung disease.
     Lung Cancer. 2025;201:108416.
     PubMed     Abstract available
     
     
     
220. NISHI T, Morita A, Hara N, Makimoto G, et al
     Efficacy of amivantamab, a bi-specific antibody targeting EGFR and MET, in ALK-rearranged non-small-cell lung cancer cell lines.
     Lung Cancer. 2025;201:108415.
     PubMed     Abstract available
     
     
     
221. LIU T, He J, Wang Y, Yang Y, et al
     Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double
     Lung Cancer. 2025;200:108108.
     PubMed     Abstract available
     
     
     
222. HOFMAN P, Ourailidis I, Romanovsky E, Ilie M, et al
     Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist.
     Lung Cancer. 2025;200:108110.
     PubMed     Abstract available
     
     
     
223. HOFMAN P, Christopoulos P, D'Haene N, Gosney J, et al
     Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer.
     Lung Cancer. 2025;201:108107.
     PubMed     Abstract available
     
     
     
224. AHMAD SQ, Pesola F, Crosbie PAJ, Gabe R, et al
     Adherence to community-based lung cancer screening in the Yorkshire Lung Screening Trial.
     Lung Cancer. 2025;200:108086.
     PubMed     Abstract available
     
     
     
225. LEE KH, Lee JS, Sugawara S, Kang JH, et al
     First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
     Lung Cancer. 2025;201:108109.
     PubMed     Abstract available
     
     
     
226. MUNOZ OM, Delgado Leon BD, Selles EG, Enguix-Riego MV, et al
     Association of single nucleotide polymorphisms rs7459185 of the HSPbeta1 gene and the risk of hematological toxicity in lung cancer.
     Lung Cancer. 2025;200:108103.
     PubMed     Abstract available
     
     
     
227. GRIDELLI C, Mok T, Janne P, Passaro A, et al
     Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT).
     Lung Cancer. 2025;201:108100.
     PubMed     Abstract available
     
     
     
228. FUJII K, Ueki M, Morishita M, Ikushima H, et al
     Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database.
     Lung Cancer. 2025;200:108099.
     PubMed     Abstract available
     
     
     
229. MULLALLY WJ, O'Leary CG, O'Byrne KJ
     Rearranged during transfection (RET) lung cancer - Update on targeted therapies.
     Lung Cancer. 2025;200:108083.
     PubMed     Abstract available
     
     
     
230. DECOSTER L, Camidge DR, Fletcher JA, Addeo A, et al
     Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group.
     Lung Cancer. 2025;200:108087.
     PubMed     Abstract available
     
     
     
231. WU L, Tian JY, Li MJ, Jiang F, et al
     Validation of the 9th edition of the TNM staging system for limited-stage small cell lung cancer after Resection: A multicenter study.
     Lung Cancer. 2025;200:108085.
     PubMed     Abstract available
     
     
     
232. TESEMA GA, Stirling RG, Wah W, Tessema ZT, et al
     Geographic variation in delay to surgical treatment among non-small cell lung cancer patients.
     Lung Cancer. 2025;199:108077.
     PubMed     Abstract available
     
     
     
233. LI Y, Law J, Le LW, Li JJN, et al
     Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.
     Lung Cancer. 2025;199:108080.
     PubMed     Abstract available
     
     
     
234. WU Y, Tang Y, Huang W, Zhu C, et al
     Improving the screening ability of neuron-specific enolase on small cell lung cancer.
     Lung Cancer. 2025;199:108078.
     PubMed     Abstract available
     
     
     
235. FUJIMOTO D, Shibaki R, Kimura K, Haratani K, et al
     Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.
     Lung Cancer. 2025;199:108079.
     PubMed     Abstract available
     
     
     
236. SAW SPL, Zhong WZ, Fu R, Li MSC, et al
     Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer.
     Lung Cancer. 2025;200:108076.
     PubMed     Abstract available
     
     
     
237. NANAMI H, Matsumoto Y, Furuse H, Tanaka M, et al
     Efficacy of cryobiopsy during medical thoracoscopy for diagnosing malignant pleural mesothelioma.
     Lung Cancer. 2025;199:108074.
     PubMed     Abstract available
     
     
     
238. THUNNISSEN E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, et al
     A reproducibility study on invasion in small pulmonary adenocarcinoma according to the WHO and a modified classification, supported by biomarkers.
     Lung Cancer. 2025;199:108060.
     PubMed     Abstract available
     
     
     
239. TSUI DCC, Lee JK, Tambaoan CFB, Hughes J, et al
     Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
     Lung Cancer. 2025;199:108081.
     PubMed     Abstract available
     
     
     
240. WU M, Zhou N, Guan M, Wang Y, et al
     Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53.
     Lung Cancer. 2025;199:108068.
     PubMed     Abstract available
     
     
     
241. SHIELDS MD, Minton KG, Tran M, Gunderman PR, et al
     Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors.
     Lung Cancer. 2025;199:108035.
     PubMed     Abstract available
     
     
     
242. VOLMONEN KK, Ronty MJ, Sederholm A, Paajanen JI, et al
     Evaluating tumour budding could improve the new grading system for lung adenocarcinoma.
     Lung Cancer. 2025;199:108067.
     PubMed     Abstract available
     
     
     
243. LEI M, Zhang X, Hu LN, Fu S, et al
     Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.
     Lung Cancer. 2025;199:108057.
     PubMed     Abstract available
     
     
     
244. DE GIGLIO A, De Biase D, Favorito V, Maloberti T, et al
     STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status.
     Lung Cancer. 2025;199:108058.
     PubMed     Abstract available
     
     
     
245. HE L, Zhang B, Zhou C, Zhao Q, et al
     A combined model of circulating tumor DNA methylated SHOX2/SCT/HOXA7 and clinical features facilitates the discrimination of malignant from benign pulmonary nodules.
     Lung Cancer. 2025;199:108064.
     PubMed     Abstract available
     
     
     December 2024
246. OGLIARI FR, Traverso A, Barbieri S, Montagna M, et al
     Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.
     Lung Cancer. 2024;199:108075.
     PubMed     Abstract available
     
     
     
247. NAKAO M, Suzuki A, Ichinose J, Matsuura Y, et al
     Prognostic impact of the N2 subclassification and stage migration in the ninth edition of the TNM classification in surgically resected lung cancer.
     Lung Cancer. 2024;199:108073.
     PubMed     Abstract available
     
     
     
248. AGUADO-BARRERA ME, Lopez-Pleguezuelos C, Gomez-Caamano A, Calvo-Crespo P, et al
     Professional-patient discrepancies in assessing lung cancer radiotherapy symptoms: An international multicentre study.
     Lung Cancer. 2024;199:108072.
     PubMed     Abstract available
     
     
     
249. HARRIS RA, Stokes EA, Batchelor TJP, Internullo E, et al
     Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial.
     Lung Cancer. 2024;199:108070.
     PubMed     Abstract available
     
     
     
250. SZTANKOVICS D, Szalai F, Moldvai D, Danko T, et al
     Comparison of molecular subtype composition between independent sets of primary and brain metastatic small cell lung carcinoma and matched samples.
     Lung Cancer. 2024;199:108071.
     PubMed     Abstract available
     
     
     
251. WELLER M, Le Rhun E, Tsamtsouri L, Dummer R, et al
     Immunotherapy or targeted therapy with or without stereotactic radiosurgery for patients with brain metastases from melanoma or non-small cell lung cancer - The ETOP 19-21 USZ-STRIKE study.
     Lung Cancer. 2024;199:108069.
     PubMed    
     
     
     
252. SUAZO-ZEPEDA E, Viddeleer AR, Maas WJ, Postmus D, et al
     CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis.
     Lung Cancer. 2024;199:108054.
     PubMed     Abstract available
     
     
     
253. ZERDES I, Kamali C, Johannsdottir B, Blasi M, et al
     A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.
     Lung Cancer. 2024;199:108065.
     PubMed     Abstract available
     
     
     
254. MA Z, Liu Y, Bao Y, Wang M, et al
     Impact of locoregional recurrence versus distant metastasis on overall survival in patients with Non-Small cell lung cancer after Surgery: A secondary analysis of PORT-C RCT.
     Lung Cancer. 2024;199:108063.
     PubMed     Abstract available
     
     
     
255. DONG Y, Yang G, Yang Y, Zhang S, et al
     Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study.
     Lung Cancer. 2024;200:108062.
     PubMed     Abstract available
     
     
     
256. HOUDA I, Bahce I, Dickhoff C, Kroese TE, et al
     An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.
     Lung Cancer. 2024;199:108061.
     PubMed     Abstract available
     
     
     
257. GELSOMINO F, Boni L, Tiseo M, Ricciardi S, et al
     An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-201
     Lung Cancer. 2024;199:108059.
     PubMed     Abstract available
     
     
     
258. SUGISAKA J, Fujimoto D, Tamiya M, Hata A, et al
     Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.
     Lung Cancer. 2024;199:108056.
     PubMed     Abstract available
     
     
     
259. URTECHO SB, Provenzano L, Spagnoletti A, Bottiglieri A, et al
     Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.
     Lung Cancer. 2024;199:108051.
     PubMed     Abstract available
     
     
     
260. WANG M, Xu Y, Huang WT, Su WC, et al
     Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations.
     Lung Cancer. 2024;199:108053.
     PubMed     Abstract available
     
     
     
261. KARAYAMA M, Suda T, Yoh K, Usui K, et al
     Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
     Lung Cancer. 2024;198:108037.
     PubMed     Abstract available
     
     
     
262. FERNANDEZ-BUSSY S, Funes-Ferrada R, Yu Lee-Mateus A, Vaca-Cartagena BF, et al
     Diagnostic performance of Shape-Sensing Robotic-Assisted bronchoscopy with mobile Cone-Beam CT for cystic and cavitary pulmonary lesions.
     Lung Cancer. 2024;198:108029.
     PubMed     Abstract available
     
     
     
263. JOHN A, McMahon DJ, Chauhan D, Mullings S, et al
     Lorlatinib-associated weight gain and dyslipidaemia: A retrospective analysis and implications for future care.
     Lung Cancer. 2024;198:108034.
     PubMed     Abstract available
     
     
     
264. AYOADE O, Canavan ME, Caturegli G, Boffa DJ, et al
     Brief Report: Should a prior cancer history be reevaluated as an exclusion for clinical trial participation?
     Lung Cancer. 2024;198:108032.
     PubMed     Abstract available
     
     
     
265. HEIJBOER FWJ, Mulders TA, van Straten M, Moonen L, et al
     Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?
     Lung Cancer. 2024;198:108030.
     PubMed     Abstract available
     
     
     
266. VAN DER WEL JWT, Jebbink M, van den Broek D, Steinbusch LC, et al
     Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
     Lung Cancer. 2024;198:107972.
     PubMed     Abstract available
     
     
     
267. WANG L, Song B, Zhang Z, Bo B, et al
     Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial.
     Lung Cancer. 2024;198:108025.
     PubMed     Abstract available
     
     
     
268. SANTARPIA M, Aliprandi M, Claudia Spagnolo C, Avan A, et al
     NOTCH and PTP4A3 alterations emerge as novel predictive biomarkers and potential therapeutic targets in pleural mesothelioma.
     Lung Cancer. 2024;198:108024.
     PubMed     Abstract available
     
     
     November 2024
269. SWALDUZ A, Beau-Faller M, Planchard D, Mazieres J, et al
     Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.
     Lung Cancer. 2024;199:108038.
     PubMed     Abstract available
     
     
     
270. AUCLIN E, Roulleaux Dugage M, Gorria T, Vauchier C, et al
     Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials.
     Lung Cancer. 2024;199:108039.
     PubMed     Abstract available
     
     
     
271. PATIL T, Gao D, Watson A, Sakamoto M, et al
     The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
     Lung Cancer. 2024;199:108040.
     PubMed     Abstract available
     
     
     
272. JUNG W, Cho IY, Jeon KH, Yeo Y, et al
     Addressing knowledge and attitude barriers to lung cancer screening: Development and evaluation of web-based decision aid.
     Lung Cancer. 2024;198:108031.
     PubMed     Abstract available
     
     
     
273. ZENG H, Schagen SB, Hendriks LEL, Sanchez-Benavides G, et al
     Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials.
     Lung Cancer. 2024;199:108036.
     PubMed     Abstract available
     
     
     
274. YU Z, Zou J, Xu F
     The molecular subtypes of small cell lung cancer defined by key transcription factors and their clinical significance.
     Lung Cancer. 2024;198:108033.
     PubMed     Abstract available
     
     
     
275. BAHADORI S, Hosseini M
     Use of commercial WAMs for monitoring individual with lung cancer. A systematic review.
     Lung Cancer. 2024;198:108026.
     PubMed     Abstract available
     
     
     
276. OSATAPHAN S, Awidi M, Jan YJ, Gunturu K, et al
     Association between higher glucose levels and reduced survival in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.
     Lung Cancer. 2024;198:108023.
     PubMed     Abstract available
     
     
     
277. HORINOUCHI H, Murakami H, Harada H, Sobue T, et al
     Real-world status of multimodal treatment of Stage IIIA-N2 non-small cell lung cancer in Japan: Results from the SOLUTION study, a non-interventional, multicenter cohort study.
     Lung Cancer. 2024;199:108027.
     PubMed     Abstract available
     
     
     
278. KOSAKA N, Kataoka Y
     Letter regarding "The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma".
     Lung Cancer. 2024;198:108020.
     PubMed    
     
     
     
279. YU Y, Fan Y, Dong X, Li J, et al
     Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison.
     Lung Cancer. 2024;198:108018.
     PubMed     Abstract available
     
     
     
280. LIU H, Hong Q, Zheng S, Zhang M, et al
     Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer.
     Lung Cancer. 2024;198:108022.
     PubMed     Abstract available
     
     
     
281. AKAMATSU H, Koh Y, Nishio M, Goto Y, et al
     Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer.
     Lung Cancer. 2024;198:108017.
     PubMed     Abstract available
     
     
     
282. ZHANG B, Bao H, Li Z, Chen J, et al
     Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer.
     Lung Cancer. 2024;199:108021.
     PubMed     Abstract available
     
     
     
283. DONG J, Bao H
     Comment on: Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence.
     Lung Cancer. 2024;201:108019.
     PubMed    
     
     
     
284. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
     Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919].
     Lung Cancer. 2024 Nov 1:108000. doi: 10.1016/j.lungcan.2024.108000.
     PubMed    
     
     
     
285. TU X, Lu Z, Hei F, Zhang T, et al
     Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study.
     Lung Cancer. 2024;197:107998.
     PubMed     Abstract available
     
     
     
286. HE X, Yang Z, Wu F, Liang Q, et al
     Confronting synchronous multiple primary lung cancers: Navigating the intersection of challenges and opportunities.
     Lung Cancer. 2024;197:107994.
     PubMed     Abstract available
     
     
     
287. FILIPELLO F, Blaauwgeers H, Lissenberg-Witte B, Schonau A, et al
     Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma in situ overlaps with invasive patterns. Proposal for a necessary modified classification of pulmonary adenocarcinomas.
     Lung Cancer. 2024;197:107987.
     PubMed     Abstract available
     
     
     
288. XU D, Liang SQ, Su M, Yang H, et al
     Crispr-mediated genome editing reveals a preponderance of non-oncogene addictions as targetable vulnerabilities in pleural mesothelioma.
     Lung Cancer. 2024;197:107986.
     PubMed     Abstract available
     
     
     
289. ZWIERENGA F, Zhang L, Melcr J, Schuuring E, et al
     The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.
     Lung Cancer. 2024;197:107973.
     PubMed     Abstract available
     
     
     
290. TABE C, Fujita T, Taima K, Tanaka H, et al
     Highly sensitive and accurate detection of ALK-TKI resistance mutations by oligoribonucleotide interference-PCR (ORNi-PCR)-based methods.
     Lung Cancer. 2024;197:107969.
     PubMed     Abstract available
     
     
     
291. SNIDER M, Salama JK, Boyer M
     Survival and recurrence rates following SBRT or surgery in medically operable Stage I NSCLC.
     Lung Cancer. 2024;197:107962.
     PubMed     Abstract available
     
     
     
292. BRUNE MM, Savic Prince S, Vlajnic T, Chijioke O, et al
     MTAP as an emerging biomarker in thoracic malignancies.
     Lung Cancer. 2024;197:107963.
     PubMed     Abstract available
     
     
     
293. UCHIBORI A, Okada S, Shimomura M, Furuya T, et al
     Clinical impact of preoperative sarcopenia and immunonutritional impairment on postoperative outcomes in non-small cell lung cancer surgery.
     Lung Cancer. 2024;198:108004.
     PubMed     Abstract available
     
     
     
294. DAGOGO-JACK I, Cooper AJ, Johnson BE, Gainor JF, et al
     Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.
     Lung Cancer. 2024;199:108003.
     PubMed     Abstract available
     
     
     October 2024
295. VINCE M, Naqvi SMH, Pellini B, Verbosky M, et al
     Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.
     Lung Cancer. 2024;198:107999.
     PubMed     Abstract available
     
     
     
296. PISAPIA P, Russo A, De Luca C, Pepe F, et al
     The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.
     Lung Cancer. 2024;198:108002.
     PubMed     Abstract available
     
     
     
297. PANG J, Zhang Y, Wang X, Wu W, et al
     Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS.
     Lung Cancer. 2024;197:108001.
     PubMed     Abstract available
     
     
     
298. CHAN YH, Yuen-Ting C, Sin CF, Ma ESK, et al
     Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming.
     Lung Cancer. 2024;197:107996.
     PubMed     Abstract available
     
     
     
299. AY L, Steiner D, Fabikan H, Illini O, et al
     Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis.
     Lung Cancer. 2024;198:107997.
     PubMed     Abstract available
     
     
     
300. LEVY A, Berghmans T, Koller M, Fournier B, et al
     PRIMALung (EORTC-1901): PRophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients.
     Lung Cancer. 2024;198:107993.
     PubMed     Abstract available
     
     
     
301. BERTOLACCINI L, Tralongo AC, Del Re M, Facchinetti F, et al
     Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes.
     Lung Cancer. 2024;197:107990.
     PubMed     Abstract available
     
     
     
302. TEIXIDOR-VILA E, Trallero J, Puigdemont M, Vidal-Vila A, et al
     Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.
     Lung Cancer. 2024;197:107995.
     PubMed     Abstract available
     
     
     
303. BAI Z, Cheng X, Ma T, Li G, et al
     CD8+ T cells infiltrating into tumors were controlled by immune status of pulmonary lymph nodes and correlated with non-small cell lung cancer (NSCLC) patients' prognosis treated with chemoimmunotherapy.
     Lung Cancer. 2024;197:107991.
     PubMed     Abstract available
     
     
     
304. KATO Y, Udagawa H, Matsumoto S, Izumi H, et al
     Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
     Lung Cancer. 2024;197:107992.
     PubMed     Abstract available
     
     
     
305. HATA A, Katakami N, Takase N, Kibata K, et al
     Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.
     Lung Cancer. 2024;197:107988.
     PubMed     Abstract available
     
     
     
306. LI M, Soo RA
     Can therapeutic drug monitoring of lorlatinib help us design the right CROWN?
     Lung Cancer. 2024;196:107965.
     PubMed    
     
     
     
307. CHEN M, Huang Y, Jiang S, Ke C, et al
     Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.
     Lung Cancer. 2024;196:107966.
     PubMed     Abstract available
     
     
     
308. ABIA-TRUJILLO D, Funes-Ferrada R, Yu Lee-Mateus A, Barrios-Ruiz A, et al
     Cryobiopsy versus fine-needle aspiration for shape-sensing robotic-assisted sampling of small lung nodules.
     Lung Cancer. 2024;196:107967.
     PubMed     Abstract available
     
     
     
309. SHIMODA IGAWA Y, Yoshida T, Makihara R, Torasawa M, et al
     Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification.
     Lung Cancer. 2024;196:107954.
     PubMed     Abstract available
     
     
     
310. WATERHOUSE DM, Rothschild S, Dooms C, Mennecier B, et al
     Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
     Lung Cancer. 2024;196:107921.
     PubMed     Abstract available
     
     
     
311. ZHU C
     What's behind thoracic surgery explosion in young patients under the age of 40 in Wuhan after COVID-19 outbreak?
     Lung Cancer. 2024;196:107937.
     PubMed     Abstract available
     
     
     
312. YANG G, Chu Q
     Comment on: Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
     Lung Cancer. 2024;196:107938.
     PubMed    
     
     
     September 2024
313. OU SH, Kilvert H, Candlish J, Lee B, et al
     Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC).
     Lung Cancer. 2024;197:107968.
     PubMed     Abstract available
     
     
     
314. CHEN R, Donlon TA, Morris BJ, Allsopp RC, et al
     Association of alcohol with lung cancer risk in men with different growth hormone receptor genotypes.
     Lung Cancer. 2024;198:107971.
     PubMed     Abstract available
     
     
     
315. KANG DW, Park SK, Kang S, Lee EK, et al
     Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer.
     Lung Cancer. 2024;197:107970.
     PubMed     Abstract available
     
     
     
316. PLANCHARD D, Wolf J, Solomon B, Sebastian M, et al
     A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
     Lung Cancer. 2024;197:107964.
     PubMed     Abstract available
     
     
     
317. KAWAGUCHI K, Ogura T, Kaneda S, Watanabe T, et al
     A prospective multi-institutional study to verify the non-inferiority of postoperative pain in robot-assisted thoracic surgery in comparison with video-assisted thoracoscopic surgery for lung cancer: The Japanese RATS interest group 01 (J-RATSIG 01).
     Lung Cancer. 2024;196:107961.
     PubMed     Abstract available
     
     
     
318. LI L, Liu N, Zhou T, Qin X, et al
     A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy.
     Lung Cancer. 2024;196:107959.
     PubMed     Abstract available
     
     
     
319. SHIBAKI R, Fujimoto D, Miyauchi E, Tsukita Y, et al
     Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.
     Lung Cancer. 2024;196:107958.
     PubMed     Abstract available
     
     
     
320. JOHNSON M, Younan D, Kent ST, Mesa-Frias M, et al
     Real-world comparative effectiveness of sotorasib versus docetaxel in second line and beyond among patients with advanced non-small cell lung cancer (NSCLC).
     Lung Cancer. 2024;197:107960.
     PubMed     Abstract available
     
     
     
321. ZHENG MZ, Yang ZQ, Cai SL, Zheng LT, et al
     Blood-brain barrier and blood-brain tumor barrier penetrating peptide-drug conjugate as targeted therapy for the treatment of lung cancer brain metastasis.
     Lung Cancer. 2024;196:107957.
     PubMed     Abstract available
     
     
     
322. MARSHALL HM, Fong KM
     Lung cancer screening - Time for an update?
     Lung Cancer. 2024;196:107956.
     PubMed     Abstract available
     
     
     
323. MILDNER FO, Sykora MM, Hackl H, Amann A, et al
     Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC).
     Lung Cancer. 2024;196:107955.
     PubMed     Abstract available
     
     
     
324. PRESLEY CJ, Tang J, Benedict J, Grogan M, et al
     Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer.
     Lung Cancer. 2024;196:107953.
     PubMed     Abstract available
     
     
     
325. MARKS JA, Gandhi N, Halmos B, Marmarelis ME, et al
     Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histology.
     Lung Cancer. 2024;196:107935.
     PubMed     Abstract available
     
     
     
326. PEETERS S, Lau K, Stefanidis K, Yasufuku K, et al
     New diagnostic and nonsurgical local treatment modalities for early stage lung cancer.
     Lung Cancer. 2024;196:107952.
     PubMed     Abstract available
     
     
     
327. MANSFIELD AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, et al
     Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
     Lung Cancer. 2024;195:107928.
     PubMed     Abstract available
     
     
     
328. LIU KJ, Li HR, Tan QQ, Jiang T, et al
     Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
     Lung Cancer. 2024;195:107933.
     PubMed     Abstract available
     
     
     
329. NASO J, Desai A, Smith CJ, Ashara YP, et al
     Predictive value and molecular correlates of MYC immunohistochemistry and copy number gain in non-small cell lung carcinomas treated with immunotherapy.
     Lung Cancer. 2024;195:107927.
     PubMed     Abstract available
     
     
     
330. WEI Y, Wu R, Yang S, Cao Y, et al
     MiR-137 mediated high expression of TIGD1 promotes migration, invasion, and suppresses apoptosis of lung adenocarcinoma.
     Lung Cancer. 2024;195:107918.
     PubMed     Abstract available
     
     
     
331. LI Y, Xie F, Zheng Q, Zhang Y, et al
     Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study.
     Lung Cancer. 2024;195:107930.
     PubMed     Abstract available
     
     
     
332. YING L, Lu T, Tian Y, Guo H, et al
     A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel.
     Lung Cancer. 2024;195:107902.
     PubMed     Abstract available
     
     
     
333. ALIREZAIE N, Chong AL, Kommoss FKF, Sabbaghian N, et al
     Exomic and epigenomic analysis of pulmonary blastoma.
     Lung Cancer. 2024;195:107916.
     PubMed     Abstract available
     
     
     
334. OTTE N, Fraune E, Cetiner Y, Felten MK, et al
     Asbestos Surveillance Program Aachen (ASPA): Cancer mortality among asbestos exposed power industry workers.
     Lung Cancer. 2024;195:107899.
     PubMed     Abstract available
     
     
     
335. LU S, Zhang Y, Zhang G, Zhou J, et al
     Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.
     Lung Cancer. 2024;195:107901.
     PubMed     Abstract available
     
     
     August 2024
336. GRIT GF, van Geffen E, Malmberg R, van Leeuwen R, et al
     Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.
     Lung Cancer. 2024;196:107950.
     PubMed     Abstract available
     
     
     
337. LIAO D, Long M, Zhang J, Wei X, et al
     Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.
     Lung Cancer. 2024;196:107936.
     PubMed     Abstract available
     
     
     
338. FERREIRA M, Swalduz A, Greillier L, du Rusquec P, et al
     Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.
     Lung Cancer. 2024;196:107934.
     PubMed     Abstract available
     
     
     
339. MALHOTRA J, Chiappori A, Fujioka N, Hanna NH, et al
     Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
     Lung Cancer. 2024;195:107932.
     PubMed     Abstract available
     
     
     
340. TASOUDIS P, Loufopoulos G, Manaki V, Doerr M, et al
     Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis.
     Lung Cancer. 2024;195:107929.
     PubMed     Abstract available
     
     
     
341. BARSOUK A, Elghawy O, Heidlauf A, Yu C, et al
     Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.
     Lung Cancer. 2024;195:107926.
     PubMed     Abstract available
     
     
     
342. RECK M, Dziadziuszko R, Sugawara S, Kao S, et al
     Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study.
     Lung Cancer. 2024;196:107924.
     PubMed     Abstract available
     
     
     
343. CALVO V, Niazmand E, Carcereny E, Rodriguez-Abreu D, et al
     Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk.
     Lung Cancer. 2024;195:107920.
     PubMed     Abstract available
     
     
     
344. DING Y, Lei S, Wang L, Tang L, et al
     Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis.
     Lung Cancer. 2024;195:107925.
     PubMed     Abstract available
     
     
     
345. TAMIYA A, Osuga M, Harada D, Isa SI, et al
     Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naive advanced non-small cell lung cancer.
     Lung Cancer. 2024;195:107917.
     PubMed     Abstract available
     
     
     
346. BAUMAN JR, Liu G, Preeshagul I, Liu SV, et al
     Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer.
     Lung Cancer. 2024;195:107919.
     PubMed     Abstract available
     
     
     
347. GALLINA FT, Balzano V, Porciello N, Taje R, et al
     Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
     Lung Cancer. 2024;194:107900.
     PubMed    
     
     
     
348. BARGHOUT SH, Zhan LJ, Raptis S, Al-Agha F, et al
     Treatment patterns and outcomes in KRAS(G12C)-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
     Lung Cancer. 2024;194:107898.
     PubMed     Abstract available
     
     
     
349. OYA Y, Imaizumi K, Mitsudomi T
     The next-generation KRAS inhibitors...What comes after sotorasib and adagrasib?
     Lung Cancer. 2024;194:107886.
     PubMed     Abstract available
     
     
     
350. WESPISER M, Swalduz A, Perol M
     Treatment sequences in EGFR mutant advanced NSCLC.
     Lung Cancer. 2024;194:107895.
     PubMed     Abstract available
     
     
     
351. WANG Q, Liu H, Xu Z, Zhang L, et al
     Effects of pregabalin combined with tramadol/paracetamol on acute pain in patients with CT-guided puncture localization of pulmonary nodules.
     Lung Cancer. 2024;194:107888.
     PubMed     Abstract available
     
     
     
352. HUANG S, Cao C, Guo L, Li C, et al
     Comparison of the variability and diagnostic efficacy of respiratory-gated PET/CT based radiomics features with ungated PET/CT in lung lesions.
     Lung Cancer. 2024;194:107889.
     PubMed     Abstract available
     
     
     
353. DOUMA LH, Baas P, de Gooijer CJ
     First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
     Lung Cancer. 2024;194:107891.
     PubMed    
     
     
     
354. XU Y, Zhang Y, Qiang H, Zhong H, et al
     Impact of PD-L1 expression on the efficacy of first-line crizotinib in advanced ROS1-rearranged NSCLC.
     Lung Cancer. 2024;194:107892.
     PubMed     Abstract available
     
     
     
355. NIEDERMAIER B, Kou Y, Tong E, Eichinger M, et al
     CT-guided needle biopsy is not associated with increased ipsilateral pleural metastasis.
     Lung Cancer. 2024;194:107890.
     PubMed     Abstract available
     
     
     
356. SPEEL EM, Dafni U, Thunnissen E, Hendrik Ruschoff J, et al
     ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.
     Lung Cancer. 2024;194:107860.
     PubMed     Abstract available
     
     
     
357. KIM YJ, Kim S, Kim TM, Suh KJ, et al
     A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19).
     Lung Cancer. 2024;194:107870.
     PubMed     Abstract available
     
     
     
358. BYLICKI O, Guisier F, Scherpereel A, Daniel C, et al
     Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
     Lung Cancer. 2024;194:107866.
     PubMed     Abstract available
     
     
     
359. OGAWA H, Koga T, Pham NA, Bernards N, et al
     Clinical and pathological predictors of engraftment for patient-derived xenografts in lung adenocarcinoma.
     Lung Cancer. 2024;194:107863.
     PubMed     Abstract available
     
     
     
360. PROVENCIO M, Robado de Lope L, Serna-Blasco R, Nadal E, et al
     BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
     Lung Cancer. 2024;194:107865.
     PubMed     Abstract available
     
     
     
361. ARRIETA O, Caballe-Perez E, Hernandez-Pedro N, Romero-Nunez E, et al
     Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
     Lung Cancer. 2024;194:107864.
     PubMed     Abstract available
     
     
     July 2024
362. CASIRAGHI M, Cara A, Mazzella A, Girelli L, et al
     1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience.
     Lung Cancer. 2024;195:107903.
     PubMed     Abstract available
     
     
     
363. ZHENG Q, Lin X, Qi W, Yin J, et al
     NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China.
     Lung Cancer. 2024;194:107897.
     PubMed     Abstract available
     
     
     
364. FUJIMOTO D, Hayashi H, Murotani K, Toi Y, et al
     Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).
     Lung Cancer. 2024;194:107896.
     PubMed     Abstract available
     
     
     
365. ASAO T, Shukuya T, Uemura K, Kitadai R, et al
     Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospectiv
     Lung Cancer. 2024;194:107894.
     PubMed     Abstract available
     
     
     
366. BELLUOMINI L, Cesta Incani U, Smimmo A, Avancini A, et al
     Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation.
     Lung Cancer. 2024;194:107893.
     PubMed     Abstract available
     
     
     
367. JACOB M, Fournel P, Tissot C, Cadranel J, et al
     A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
     Lung Cancer. 2024;194:107868.
     PubMed     Abstract available
     
     
     
368. ZANDWIJK NV, Frank AL, Reid G, Dimitri Roe O, et al
     Asbestos-Related lung Cancer: An underappreciated oncological issue.
     Lung Cancer. 2024;194:107861.
     PubMed     Abstract available
     
     
     
369. PONS-TOSTIVINT E, Ezzedine R, Goronflot T, Crequit P, et al
     Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study.
     Lung Cancer. 2024;194:107887.
     PubMed     Abstract available
     
     
     
370. IZUMI M, Costa DB, Kobayashi SS
     Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.
     Lung Cancer. 2024;194:107885.
     PubMed     Abstract available
     
     
     
371. LI R, Xu Y, Zhao J, Zhang L, et al
     Comparison of radiotherapy versus surgical resection following neoadjuvant chemoimmunotherapy in potentially resectable stage III non-small-cell lung cancer: A propensity score matching analysis.
     Lung Cancer. 2024;194:107884.
     PubMed     Abstract available
     
     
     
372. YOSHIZAKI C, Yoshida Y, Nohmi S, Go Y, et al
     EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report.
     Lung Cancer. 2024;194:107869.
     PubMed     Abstract available
     
     
     
373. DE BRUYCKER A, Schneiders F, Gulstene S, Moghanaki D, et al
     Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights.
     Lung Cancer. 2024;193:107848.
     PubMed     Abstract available
     
     
     
374. SAW SPL, Low YF, Lai GGY, Chan LL, et al
     Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.
     Lung Cancer. 2024;193:107856.
     PubMed     Abstract available
     
     
     
375. ARMATO SG 3RD, Katz SI, Frauenfelder T, Jayasekera G, et al
     Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group.
     Lung Cancer. 2024;193:107832.
     PubMed     Abstract available
     
     
     
376. BORGHAEI H, Pundole X, Sangare L, Anderson E, et al
     Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study.
     Lung Cancer. 2024;193:107819.
     PubMed     Abstract available
     
     
     
377. FRANK AL, van Zandwijk N
     Asbestos history and use.
     Lung Cancer. 2024;193:107828.
     PubMed     Abstract available
     
     
     
378. ERNST SM, van Marion R, von der Thusen JH, Dubbink HJ, et al
     Exploring the use of circulating tumor DNA for mutational signature analysis.
     Lung Cancer. 2024;193:107844.
     PubMed    
     
     
     June 2024
379. BLANCO-VILLAR ML, Exposito-Hernandez J, Navarro-Moreno E, Lopez Martin JM, et al
     Analyzing diagnostic and treatment wait times for lung cancer Patients: Key insights from a provincial registry study.
     Lung Cancer. 2024;194:107867.
     PubMed     Abstract available
     
     
     
380. NISHIO M, Watanabe S, Udagawa H, Aragane N, et al
     Integrated analysis of older adults and patients with renal dysfunction in the IMpower130 and IMpower132 randomized controlled trials for advanced non-squamous non-small cell lung cancer.
     Lung Cancer. 2024 Jun 28:107859. doi: 10.1016/j.lungcan.2024.107859.
     PubMed     Abstract available
     
     
     
381. BUM LEE J, Huang Y, Oya Y, Nutzinger J, et al
     Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.
     Lung Cancer. 2024;194:107862.
     PubMed     Abstract available
     
     
     
382. BEN-ARYE E, Gressel O, Lifshitz S, Peled N, et al
     Integrative oncology for patients with lung cancer: A prospective pragmatic controlled trial.
     Lung Cancer. 2024;193:107857.
     PubMed     Abstract available
     
     
     
383. KLEBE S, Rathi V, Russell PA
     Lung cancer caused by asbestos: What a reporting pathologist needs to know.
     Lung Cancer. 2024;195:107849.
     PubMed     Abstract available
     
     
     
384. METINTAS M, Ak G, Metintas S
     Environmental asbestos exposure and lung cancer.
     Lung Cancer. 2024;194:107850.
     PubMed     Abstract available
     
     
     
385. ASANO Y, Yamamoto N, Demura S, Hayashi K, et al
     Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases.
     Lung Cancer. 2024;193:107858.
     PubMed     Abstract available
     
     
     
386. TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
     Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platin
     Lung Cancer. 2024 Jun 17:107852. doi: 10.1016/j.lungcan.2024.107852.
     PubMed    
     
     
     
387. CUPPENS K, Du Pont B, Knegjens J, Maes B, et al
     Immune checkpoint inhibition in early-stage non-small cell lung cancer.
     Lung Cancer. 2024;193:107855.
     PubMed     Abstract available
     
     
     
388. APTEKAR J, Jain R, Korytowsky B, Shafquat A, et al
     Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis.
     Lung Cancer. 2024;193:107854.
     PubMed     Abstract available
     
     
     
389. ARRIETA O
     In response to "On the Hispanic paradox in lung cancer".
     Lung Cancer. 2024;193:107853.
     PubMed    
     
     
     
390. GAO X, Tan H, Zhu M, Zhang G, et al
     Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis.
     Lung Cancer. 2024;193:107851.
     PubMed     Abstract available
     
     
     
391. MAHMOOD K, Wang H, Ji Z, Giovacchini CX, et al
     Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing.
     Lung Cancer. 2024;193:107847.
     PubMed     Abstract available
     
     
     
392. HUANG L, Petersen RH
     Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer.
     Lung Cancer. 2024;193:107846.
     PubMed     Abstract available
     
     
     
393. GOTO E, Taki T, Nomura K, Miyakami Y, et al
     Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
     Lung Cancer. 2024;192:107830.
     PubMed     Abstract available
     
     
     
394. LI M, Zhang Y, Zhou P, Miao Y, et al
     Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor.
     Lung Cancer. 2024;192:107825.
     PubMed     Abstract available
     
     
     
395. VORUGANTI MADDALI IS, Cunningham C, McLeod L, Bahig H, et al
     Optimal management of radiation pneumonitis: Findings of an international Delphi consensus study.
     Lung Cancer. 2024;192:107822.
     PubMed     Abstract available
     
     
     
396. SHI M, Pang L, Zhou H, Mo S, et al
     Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods.
     Lung Cancer. 2024;192:107818.
     PubMed     Abstract available
     
     
     
397. SZENTKERESZTY M, Ladanyi A, Galffy G, Tovari J, et al
     Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma.
     Lung Cancer. 2024;192:107824.
     PubMed     Abstract available
     
     
     
398. CHEN Q, Xia L, Wang J, Zhu S, et al
     EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment.
     Lung Cancer. 2024;192:107815.
     PubMed     Abstract available
     
     
     
399. SHAH R, Sun L, Ridge CA
     Image guided lung biopsy.
     Lung Cancer. 2024;192:107803.
     PubMed     Abstract available
     
     
     
400. MARTIN A, Carton M, Thery L, Burnod A, et al
     Palliative care integration and end-of-life care intensity for patients with NSCLC.
     Lung Cancer. 2024;192:107800.
     PubMed     Abstract available
     
     
     
401. ISHIDOYA M, Makiguchi T, Tanaka H, Miura T, et al
     Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
     Lung Cancer. 2024;192:107790.
     PubMed     Abstract available
     
     
     
402. KLOTZ LV, Casjens S, Johnen G, Taeger D, et al
     Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients.
     Lung Cancer. 2024;192:107802.
     PubMed     Abstract available
     
     
     May 2024
403. AMARI L, Tomasini P, Dantony E, Rousseau-Bussac G, et al
     Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC
     Lung Cancer. 2024;193:107843.
     PubMed     Abstract available
     
     
     
404. PENG L, Lidan H, Cuicui Z, Zhe Z, et al
     DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer.
     Lung Cancer. 2024;192:107831.
     PubMed     Abstract available
     
     
     
405. KE H, Kao S, van Zandwijk N, Rasko JEJ, et al
     Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer.
     Lung Cancer. 2024;192:107829.
     PubMed     Abstract available
     
     
     
406. LUNDBERG FE, Ekman S, Johansson ALV, Engholm G, et al
     Trends in lung cancer survival in the Nordic countries 1990-2016: The NORDCAN survival studies.
     Lung Cancer. 2024;192:107826.
     PubMed     Abstract available
     
     
     
407. HUANG Z, Zhang Y, Xu Q, Song L, et al
     Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
     Lung Cancer. 2024;192:107827.
     PubMed     Abstract available
     
     
     
408. LI Y, Wong M, Zhan L, Corke L, et al
     Single organ metastatic sites in non-small cell lung cancer: Patient characteristics, treatment patterns and outcomes from a large retrospective Canadian cohort.
     Lung Cancer. 2024;192:107823.
     PubMed     Abstract available
     
     
     
409. BARAMIDZE A, Makharadze T, Gogishvili M, Melkadze T, et al
     Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 >/= 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.
     Lung Cancer. 2024;193:107821.
     PubMed     Abstract available
     
     
     
410. FELIP E, Metro G, Tan DSW, Wolf J, et al
     Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
     Lung Cancer. 2024;192:107820.
     PubMed     Abstract available
     
     
     
411. NADAL E, Rifi N, Kane S, Mbacke S, et al
     Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
     Lung Cancer. 2024;192:107816.
     PubMed     Abstract available
     
     
     
412. WANG Z, Li X, Chen J, Hua Y, et al
     The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma.
     Lung Cancer. 2024;192:107817.
     PubMed     Abstract available
     
     
     
413. WANG L, Li L, Zhou X, Zhang D, et al
     Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
     Lung Cancer. 2024;191:107797.
     PubMed    
     
     
     
414. LU YF, Chang YH, Chen YJ, Hsieh MS, et al
     Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
     Lung Cancer. 2024;191:107791.
     PubMed     Abstract available
     
     
     
415. CHOUR A, Basse C, Lebosse F, Bonte PE, et al
     Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
     Lung Cancer. 2024;191:107789.
     PubMed     Abstract available
     
     
     
416. MIYAKOSHI J, Yoshida T, Kashima J, Shirasawa M, et al
     Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
     Lung Cancer. 2024;191:107788.
     PubMed     Abstract available
     
     
     
417. NISHIMURA T, Fujimoto H
     Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?
     Lung Cancer. 2024;191:107561.
     PubMed    
     
     
     
418. HOCKING AJ, Mortimer LA, Farrall AL, Russell PA, et al
     Establishing mesothelioma patient-derived organoid models from malignant pleural effusions.
     Lung Cancer. 2024;191:107542.
     PubMed     Abstract available
     
     
     
419. LIU G, Mazieres J, Stratmann J, Ou SI, et al
     A pragmatic guide for management of adverse events associated with lorlatinib.
     Lung Cancer. 2024;191:107535.
     PubMed     Abstract available
     
     
     April 2024
420. OKAHISA M, Udagawa H, Matsumoto S, Kato T, et al
     Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
     Lung Cancer. 2024;191:107798.
     PubMed     Abstract available
     
     
     
421. ZHANG SL, Tian Y, Yu J, Zhang JH, et al
     Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
     Lung Cancer. 2024;191:107799.
     PubMed     Abstract available
     
     
     
422. BADE BC, Zhao J, Li F, Tanoue L, et al
     Trends and predictors of Quality of Life in lung cancer survivors.
     Lung Cancer. 2024;191:107793.
     PubMed     Abstract available
     
     
     
423. LIU S, Graves N, Tan AC
     The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
     Lung Cancer. 2024;191:107794.
     PubMed     Abstract available
     
     
     
424. DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
     The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
     Lung Cancer. 2024;191:107792.
     PubMed     Abstract available
     
     
     
425. MALAPELLE U, Passiglia F, Pepe F, Pisapia P, et al
     The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database.
     Lung Cancer. 2024;191:107787.
     PubMed     Abstract available
     
     
     
426. TAVERNA JA, Hung CN, Williams M, Williams R, et al
     Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
     Lung Cancer. 2024;190:107533.
     PubMed     Abstract available
     
     
     
427. JUNG HA, Park B, Park S, Sun JM, et al
     Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
     Lung Cancer. 2024;190:107536.
     PubMed     Abstract available
     
     
     
428. YU T, Zhou X, Li M
     Comment on: Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas.
     Lung Cancer. 2024;190:107534.
     PubMed    
     
     
     
429. PANG LL, Zhuang WT, Huang YH, Liao J, et al
     Uncommon de novo EGFR(T790M)-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment.
     Lung Cancer. 2024;190:107528.
     PubMed     Abstract available
     
     
     
430. DAMHUIS RAM, Dickhoff C, Bahce I, Senan S, et al
     Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
     Lung Cancer. 2024;190:107532.
     PubMed     Abstract available
     
     
     
431. SLATORE CG, Hooker ER, Shull S, Golden SE, et al
     Association of patient and health care organization factors with incidental nodule guidelines adherence: A multi-system observational study.
     Lung Cancer. 2024;190:107526.
     PubMed     Abstract available
     
     
     
432. SUN L, Handorf EA, Zhou Y, Borghaei H, et al
     Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
     Lung Cancer. 2024;190:107510.
     PubMed     Abstract available
     
     
     
433. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Carcereny E, et al
     Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
     Lung Cancer. 2024;190:107513.
     PubMed     Abstract available
     
     
     
434. HONG DS, Cappuzzo F, Chul Cho B, Dowlati A, et al
     Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.
     Lung Cancer. 2024;190:107512.
     PubMed     Abstract available
     
     
     March 2024
435. GABRIEL L, McVeigh T, Macmahon S, Avila Z, et al
     Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family.
     Lung Cancer. 2024;191:107543.
     PubMed     Abstract available
     
     
     
436. LYHNE CHRISTENSEN N, Gouliaev A, McPhail S, Lyratzopoulos G, et al
     Lung cancer among the Elderly in Denmark - A comprehensive population-based cohort study.
     Lung Cancer. 2024;191:107555.
     PubMed     Abstract available
     
     
     
437. SUN M, Feng Q, Yan Q, Zhao H, et al
     Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer.
     Lung Cancer. 2024;190:107541.
     PubMed     Abstract available
     
     
     
438. TOZUKA T, Noro R, Mizutani H, Kurimoto F, et al
     Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
     Lung Cancer. 2024;191:107540.
     PubMed     Abstract available
     
     
     
439. RODRIGUEZ J
     On the Hispanic paradox in lung cancer.
     Lung Cancer. 2024;190:107537.
     PubMed    
     
     
     
440. GUDINA AT, Kamen C, Hardy SJ, Kehoe L, et al
     Revisiting the lung cancer screening eligibility criteria to promote equity for Black individuals.
     Lung Cancer. 2024;191:107539.
     PubMed     Abstract available
     
     
     
441. PU X, Xiao Z, Li J, Wu Z, et al
     Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
     Lung Cancer. 2024;191:107538.
     PubMed     Abstract available
     
     
     
442. WALLACE ND, Alexander M, Xie J, Ball D, et al
     The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
     Lung Cancer. 2024;190:107531.
     PubMed     Abstract available
     
     
     
443. KIM DW, Chul Cho B, Pachipala K, Kim SW, et al
     Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
     Lung Cancer. 2024;190:107530.
     PubMed     Abstract available
     
     
     
444. CONNOR WELLS J, Mullin MM, Ho C, Melosky B, et al
     Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.
     Lung Cancer. 2024;190:107529.
     PubMed     Abstract available
     
     
     
445. KRAUS KM, Oreshko M, Schnabel JA, Bernhardt D, et al
     Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.
     Lung Cancer. 2024;189:107507.
     PubMed     Abstract available
     
     
     
446. KAIRA K, Imai H, Kagamu H
     Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
     Lung Cancer. 2024;189:107501.
     PubMed    
     
     
     
447. ZHOU P, Fu Y, Tang Y, Jiang L, et al
     Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
     Lung Cancer. 2024;189:107471.
     PubMed     Abstract available
     
     
     
448. MOLINA TJ, Roden AC, Szolkowska M, Shimizu S, et al
     International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study.
     Lung Cancer. 2024;189:107479.
     PubMed     Abstract available
     
     
     
449. KLOKER LD, Sidiras M, Flaadt T, Brecht IB, et al
     Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
     Lung Cancer. 2024;189:107496.
     PubMed     Abstract available
     
     
     
450. FITZGERALD SM
     Resolving asbestos and ultrafine particulate definitions with carcinogenicity.
     Lung Cancer. 2024;189:107478.
     PubMed     Abstract available
     
     
     
451. STARES M, Doyle E, Chapple S, Raynes G, et al
     Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab.
     Lung Cancer. 2024;189:107497.
     PubMed     Abstract available
     
     
     
452. CHEN Y, Chen H, Yu R, Zeng X, et al
     Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.
     Lung Cancer. 2024;189:107476.
     PubMed     Abstract available
     
     
     February 2024
453. GOULIAEV A, Ali F, Jakobsen E, Dalton SO, et al
     The Danish lung cancer registry: A nationwide validation study.
     Lung Cancer. 2024;190:107527.
     PubMed     Abstract available
     
     
     
454. LEE JD, Zheng R, Okusanya OT, Evans NR 3rd, et al
     Association between surgical quality and long-term survival in lung cancer.
     Lung Cancer. 2024;190:107511.
     PubMed     Abstract available
     
     
     
455. SAEKI Y, Maki N, Nemoto T, Inada K, et al
     Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array.
     Lung Cancer. 2024;190:107514.
     PubMed     Abstract available
     
     
     
456. CHUL CHO B, Han JY, Hyeong Lee K, Lee YG, et al
     Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
     Lung Cancer. 2024;190:107509.
     PubMed     Abstract available
     
     
     
457. BAPTISTE OUDART J, Garinet S, Leger C, Barlesi F, et al
     STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
     Lung Cancer. 2024;190:107508.
     PubMed     Abstract available
     
     
     
458. BAR J, Esteban E, Rodriguez-Abreu D, Aix SP, et al
     Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
     Lung Cancer. 2024;190:107506.
     PubMed     Abstract available
     
     
     
459. SAAL J, Bald T, Eckstein M, Ralser DJ, et al
     Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibition.
     Lung Cancer. 2024;189:107505.
     PubMed     Abstract available
     
     
     
460. LAESEKE P, Ng C, Naghi A, Wright GWJ, et al
     Response to letter: Microwave ablation for Early-Stage Non-Small cell Lung Cancer: Don't Put the Cart before the stereotactic Horse.
     Lung Cancer. 2024;189:107504.
     PubMed    
     
     
     
461. WANG S, Hao X, Dai L, Lou N, et al
     Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
     Lung Cancer. 2024;189:107503.
     PubMed     Abstract available
     
     
     
462. SAIGI M, Mate JL, Carcereny E, Martinez-Cardus A, et al
     HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer.
     Lung Cancer. 2024;189:107502.
     PubMed     Abstract available
     
     
     
463. KUNIMASA K, Tamiya M, Inoue T, Kawamura T, et al
     Clinical application of the Lung Cancer Compact Panel(TM) using various types of cytological specimens in patients with lung cancer.
     Lung Cancer. 2024;189:107498.
     PubMed     Abstract available
     
     
     
464. LIU SV, Frohn C, Minasi L, Fernamberg K, et al
     Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
     Lung Cancer. 2024;188:107469.
     PubMed     Abstract available
     
     
     
465. ZHANG YH, Liu XS, Gao Y, Yuan LL, et al
     SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with (18)F-FDG metabolic parameters.
     Lung Cancer. 2024;188:107449.
     PubMed     Abstract available
     
     
     
466. KITAGAWA S, Zenke Y, Taki T, Aokage K, et al
     Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
     Lung Cancer. 2024;188:107453.
     PubMed     Abstract available
     
     
     
467. BURNS L, Tukachinsky H, Raskina K, Huang RSP, et al
     Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
     Lung Cancer. 2024;188:107454.
     PubMed     Abstract available
     
     
     January 2024
468. WANG Y, Hu C, Yu H, Hu J, et al
     Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.
     Lung Cancer. 2024;189:107495.
     PubMed     Abstract available
     
     
     
469. HUANG S, Zhao M, Li S, Chen T, et al
     Incorporation of the lepidic component as an additional pathological T descriptor for non-small cell lung cancer: Data from 3335 cases of lung adenocarcinoma.
     Lung Cancer. 2024;189:107472.
     PubMed     Abstract available
     
     
     
470. GENET SAAM, Visser E, Youssef-El Soud M, Belderbos HNA, et al
     Strengths and challenges in current lung cancer care: Timeliness and diagnostic procedures in six Dutch hospitals.
     Lung Cancer. 2024;189:107477.
     PubMed     Abstract available
     
     
     
471. WU H, Zhang Q, Zhai W, Chen Y, et al
     Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
     Lung Cancer. 2024;188:107475.
     PubMed     Abstract available
     
     
     
472. VAN ZANDWIJK N, Frank AL
     A multidisciplinary review of several aspects of Asbestos-Related Lung Cancer (ARLC).
     Lung Cancer. 2024 Jan 17:107474. doi: 10.1016/j.lungcan.2024.107474.
     PubMed    
     
     
     
473. PAZ-ARES L, Goto Y, Wan-Teck Lim D, Halmos B, et al
     Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase
     Lung Cancer. 2024;189:107451.
     PubMed     Abstract available
     
     
     
474. NORITAKE O, Nakamura S, Kinoshita F, Aokage K, et al
     Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis.
     Lung Cancer. 2024;188:107470.
     PubMed     Abstract available
     
     
     
475. CHIANG CL, Huang HC, Luo YH, Shen CI, et al
     Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
     Lung Cancer. 2024;188:107473.
     PubMed     Abstract available
     
     
     
476. ZHAO S, Ma Y, Liu L, Fang J, et al
     Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
     Lung Cancer. 2024;188:107468.
     PubMed     Abstract available
     
     
     
477. PASSIGLIA F, Lucia Reale M, Lo Russo G, Pasello G, et al
     Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program.
     Lung Cancer. 2024;187:107444.
     PubMed     Abstract available
     
     
     
478. MIKUBO M, Tamagawa S, Kondo Y, Hayashi S, et al
     Micropapillary and solid components as high-grade patterns in IASLC grading system of lung adenocarcinoma: Clinical implications and management.
     Lung Cancer. 2024;187:107445.
     PubMed     Abstract available
     
     
     
479. GAO J, Ao Y, Wang S, Chen Z, et al
     WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors.
     Lung Cancer. 2024;187:107446.
     PubMed     Abstract available
     
     
     
480. GAO L, Ai X, Lu S
     ETV6::NTRK3 gene fusion in a patient with metastatic lung atypical carcinoid successfully treated with repotrectinib: A case report.
     Lung Cancer. 2024;187:107443.
     PubMed     Abstract available
     
     
     
481. DUMOULIN DW, Douma LH, Hofman MM, van der Noort V, et al
     Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma.
     Lung Cancer. 2024;187:107440.
     PubMed     Abstract available
     
     
     
482. LEBOUILLE-VELDMAN AB, Taros TN, Nawabi NLA, Mekary RA, et al
     Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases.
     Lung Cancer. 2024;187:107425.
     PubMed     Abstract available
     
     
     December 2023
483. CHENG Y, Wu L, Huang D, Wang Q, et al
     Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
     Lung Cancer. 2023;188:107455.
     PubMed     Abstract available
     
     
     
484. SAKATA Y, Saito G, Sakata S, Oya Y, et al
     Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
     Lung Cancer. 2023 Dec 29:107450. doi: 10.1016/j.lungcan.2023.107450.
     PubMed    
     
     
     
485. PETERS S, Trigo J, Besse B, Moreno V, et al
     Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval >/=30 days and without central nervous metastases.
     Lung Cancer. 2023;188:107448.
     PubMed     Abstract available
     
     
     
486. TAKAM KAMGA P, Mayenga M, Sebane L, Costantini A, et al
     Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
     Lung Cancer. 2023;188:107447.
     PubMed     Abstract available
     
     
     
487. STUART CM, Dyas AR, Bronsert MR, Velopulos CG, et al
     The Effect of Social Vulnerability on Initial Stage and Treatment for Non-Small Cell Lung Cancer.
     Lung Cancer. 2023;188:107452.
     PubMed     Abstract available
     
     
     
488. GRIDELLI C, Peters S, Mok T, Garassino M, et al
     Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
     Lung Cancer. 2023;187:107441.
     PubMed     Abstract available
     
     
     
489. CHO BC, Chiu CH, Massarelli E, Buchschacher GL, et al
     Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
     Lung Cancer. 2023;188:107442.
     PubMed     Abstract available
     
     
     
490. WANG L, Diao M, Zhang Z, Jiang M, et al
     Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
     Lung Cancer. 2023;187:107439.
     PubMed     Abstract available
     
     
     
491. CAVAZZONI A, Digiacomo G, Volta F, Alfieri R, et al
     PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
     Lung Cancer. 2023;187:107438.
     PubMed     Abstract available
     
     
     
492. NASH J, Brims F
     International standards of care in thoracic oncology: A narrative review of clinical quality indicators.
     Lung Cancer. 2023;186:107421.
     PubMed     Abstract available
     
     
     
493. AKRAM F, Wolf JL, Trandafir TE, Dingemans AC, et al
     Artificial intelligence-based recurrence prediction outperforms classical histopathological methods in pulmonary adenocarcinoma biopsies.
     Lung Cancer. 2023;186:107413.
     PubMed     Abstract available
     
     
     
494. LIU Z, Wu Q, Li W, Li P, et al
     A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
     Lung Cancer. 2023;186:107386.
     PubMed     Abstract available
     
     
     
495. LINGLING X, Maoxi C, Wei Y, Jieting Z, et al
     Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
     Lung Cancer. 2023;186:107415.
     PubMed     Abstract available
     
     
     
496. SCHMALZ L, Bloomer C, Zhang W, Petty W, et al
     Durable response to amivantamab in treatment refractory NSCLC harboring EGFR and complex MET mutations: A case report.
     Lung Cancer. 2023;186:107400.
     PubMed     Abstract available
     
     
     
497. YIN X, Li J, Chen B, Liu K, et al
     The predictive value of (18)F-FDG PET/CT combined with inflammatory index for major pathological reactions in resectable NSCLC receiving neoadjuvant immunochemotherapy.
     Lung Cancer. 2023;186:107389.
     PubMed     Abstract available
     
     
     
498. SUN J, Zhang L, Hu B, Du Z, et al
     Deep learning-based solid component measuring enabled interpretable prediction of tumor invasiveness for lung adenocarcinoma.
     Lung Cancer. 2023;186:107392.
     PubMed     Abstract available
     
     
     November 2023
499. SCHULER A, Huser J, Schmid S, Schar S, et al
     Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
     Lung Cancer. 2023;187:107427.
     PubMed     Abstract available
     
     
     
500. SAKATA Y, Saito G, Sakata S, Oya Y, et al
     Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP).
     Lung Cancer. 2023;186:107426.
     PubMed     Abstract available
     
     
     
501. LIVANOU ME, Syrigos NK, Montgomery A, Moeckel C, et al
     Eligibility for screening with low-dose CT in a real-world cohort of patients with lung cancer in Greece: A brief report.
     Lung Cancer. 2023;186:107424.
     PubMed     Abstract available
     
     
     
502. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
     Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
     Lung Cancer. 2023;186:107422.
     PubMed     Abstract available
     
     
     
503. KOCHER WULFECK M, Plesner S, Herndon JE 2nd, Christensen JD, et al
     Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program.
     Lung Cancer. 2023;186:107420.
     PubMed     Abstract available
     
     
     
504. MAJEM M, Basch E, Cella D, Garon EB, et al
     Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review.
     Lung Cancer. 2023;187:107419.
     PubMed     Abstract available
     
     
     
505. KATO T, Casarini I, Cobo M, Faivre-Finn C, et al
     Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
     Lung Cancer. 2023;187:107414.
     PubMed     Abstract available
     
     
     October 2023
506. LIU SV, Mok TSK, Nabet BY, Mansfield AS, et al
     Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
     Lung Cancer. 2023;186:107418.
     PubMed     Abstract available
     
     
     
507. MANGLAVITI S, Bini M, Apollonio G, Zecca E, et al
     High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
     Lung Cancer. 2023;186:107417.
     PubMed     Abstract available
     
     
     
508. FURUNE S, Ando Y
     Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.
     Lung Cancer. 2023;186:107416.
     PubMed    
     
     
     
509. KIM W, Lee SC, Lee WR, Chun S, et al
     The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea.
     Lung Cancer. 2023;186:107412.
     PubMed     Abstract available
     
     
     
510. HUANG S, Wu J, Li S, Li X, et al
     Evaluation of combined pathological responses in primary tumor and lymph nodes following neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
     Lung Cancer. 2023;186:107401.
     PubMed     Abstract available
     
     
     
511. DEHEM A, Mazieres J, Chour A, Guisier F, et al
     Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).
     Lung Cancer. 2023;186:107393.
     PubMed     Abstract available
     
     
     
512. MORETTI A, Kovacevic B, Vilmann P, Annema JT, et al
     Performance of EUS-FNA and EUS-B-FNA for the diagnosis of left adrenal glands metastases in patients with lung cancer: A systematic review and meta-analysis.
     Lung Cancer. 2023;186:107391.
     PubMed     Abstract available
     
     
     
513. RYU WK, Yong SH, Lee SH, Gwon HR, et al
     Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer.
     Lung Cancer. 2023;186:107390.
     PubMed     Abstract available
     
     
     
514. RUGGIRELLO M, Valsecchi C, Ledda RE, Sabia F, et al
     Long-term outcomes of lung cancer screening in males and females.
     Lung Cancer. 2023;185:107387.
     PubMed     Abstract available
     
     
     
515. LIM TKH, Skoulidis F, Kerr KM, Ahn MJ, et al
     KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
     Lung Cancer. 2023;184:107293.
     PubMed     Abstract available
     
     
     
516. HO H, Yu SL, Chen HY, Yuan SS, et al
     Whole exome sequencing and MicroRNA profiling of lung adenocarcinoma identified risk prediction features for tumors at stage I and its substages.
     Lung Cancer. 2023;184:107352.
     PubMed     Abstract available
     
     
     
517. MATSUNAGA T, Suzuki K, Hattori A, Fukui M, et al
     A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid component in part-solid tumor.
     Lung Cancer. 2023;184:107354.
     PubMed     Abstract available
     
     
     
518. LINDBERG K
     Balancing tumour control probability and toxicity in SBRT of ultra-central lung tumours - One step forward.
     Lung Cancer. 2023;184:107343.
     PubMed    
     
     
     
519. GOTO E, Takamochi K, Kishikawa S, Hayashi T, et al
     Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics.
     Lung Cancer. 2023;184:107348.
     PubMed     Abstract available
     
     
     
520. QI R, Fu X, Yu Y, Xu H, et al
     Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study.
     Lung Cancer. 2023;184:107346.
     PubMed     Abstract available
     
     
     
521. SEKER-CIN H, Tay TKY, Kazdal D, Kluck K, et al
     Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
     Lung Cancer. 2023;184:107317.
     PubMed     Abstract available
     
     
     
522. ZIRANU P, Ferrari PA, Guerrera F, Bertoglio P, et al
     Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score.
     Lung Cancer. 2023;184:107342.
     PubMed     Abstract available
     
     
     
523. YEUNG V, Zaemes J, Yeh J, Giancarlo C, et al
     High levels of expression of Trop-2 in thymic epithelial tumors.
     Lung Cancer. 2023;184:107324.
     PubMed     Abstract available
     
     
     
524. GEMINE RE, Davies GR, Lanyon K, Rees SE, et al
     Quitting smoking improves two-year survival after a diagnosis of non-small cell lung cancer.
     Lung Cancer. 2023;186:107388.
     PubMed     Abstract available
     
     
     September 2023
525. NUTZINGER J, Bum Lee J, Li Low J, Ling Chia P, et al
     Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
     Lung Cancer. 2023;186:107385.
     PubMed     Abstract available
     
     
     
526. CHOW R, McMillan MT, Simone CB 2nd
     Microwave Ablation for Early-Stage Non-Small Cell Lung Cancer: Don't Put the Cart Before the Stereotactic Horse.
     Lung Cancer. 2023;185:107382.
     PubMed    
     
     
     
527. ZHANG Y, Li N, Dong Y, Wang W, et al
     Spatial microenvironment heterogeneity in therapy-naive lung cancer: A concept with more attention needed.
     Lung Cancer. 2023;185:107384.
     PubMed    
     
     
     
528. DAGOGO-JACK I, Kiedrowski LA, Lennerz JK
     Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.
     Lung Cancer. 2023;186:107383.
     PubMed     Abstract available
     
     
     
529. FALCHERO L, Guisier F, Darrason M, Boyer A, et al
     Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
     Lung Cancer. 2023;185:107379.
     PubMed     Abstract available
     
     
     
530. KRAMER T, Kuijvenhoven JC, von der Thusen J, Cohen D, et al
     Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: A randomized clinical trial.
     Lung Cancer. 2023;185:107362.
     PubMed     Abstract available
     
     
     
531. PARRA-MEDINA R, Pablo Castaneda-Gonzalez J, Montoya L, Paula Gomez-Gomez M, et al
     Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. A systematic review and meta-analysis.
     Lung Cancer. 2023;185:107378.
     PubMed     Abstract available
     
     
     
532. GARCIA CAMPELO MR, Wan Y, Lin HM, Chen T, et al
     Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.
     Lung Cancer. 2023;185:107376.
     PubMed     Abstract available
     
     
     
533. BOESCHEN M, Kuhn CK, Wirtz H, Seyfarth HJ, et al
     Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
     Lung Cancer. 2023;184:107361.
     PubMed     Abstract available
     
     
     
534. PORTA C, Pradelli L, Sicari E, Castellani S, et al
     Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
     Lung Cancer. 2023;185:107359.
     PubMed     Abstract available
     
     
     
535. HAN D, Zhu Y, Choudhry AA, Cheng J, et al
     Association of telomere length with risk of lung cancer: A large prospective cohort study from the UK Biobank.
     Lung Cancer. 2023;184:107358.
     PubMed     Abstract available
     
     
     August 2023
536. ZHAO Y, Ma Y, Fan Y, Zhou J, et al
     A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
     Lung Cancer. 2023;184:107355.
     PubMed     Abstract available
     
     
     
537. KU HY, Lin SM, Wang CL, Lo YC, et al
     Impact of pathological nodal staging and tumour differentiation on survival and postoperative radiotherapy in completely resected stage IIIA Non-small-cell lung cancer.
     Lung Cancer. 2023;184:107357.
     PubMed     Abstract available
     
     
     
538. ZENG L, Zhou Y, Xu Q, Huang Z, et al
     Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.
     Lung Cancer. 2023;184:107350.
     PubMed     Abstract available
     
     
     
539. LEFEBVRE AM, Adam J, Nicolazzi C, Larois C, et al
     The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
     Lung Cancer. 2023;184:107356.
     PubMed     Abstract available
     
     
     
540. BOZORGMEHR F, Muller A, Rawluk J, Sianidou M, et al
     Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment?
     Lung Cancer. 2023;184:107340.
     PubMed     Abstract available
     
     
     
541. LEVALLET G, Dubois F, Elie N, Creveuil C, et al
     VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
     Lung Cancer. 2023;182:107287.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.